

PCT


WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 5 : C12Q 1/68	A1	(11) International Publication Number: WO 91/02818 (43) International Publication Date: 7 March 1991 (07.03.91)
(21) International Application Number: PCT/US90/04733 (22) International Filing Date: 23 August 1990 (23.08.90) (30) Priority data: 397,681 23 August 1989 (23.08.89) US (60) Parent Application or Grant (63) Related by Continuation US 397,681 (CIP) Filed on 23 August 1989 (23.08.89) (71) Applicant (for all designated States except US): CANGENE CORPORATION [CA/CA]; 3403 American Drive, Mississauga, Ontario L4V 1TA (CA).		(72) Inventors; and (75) Inventors/Applicants (for US only) : MALEK, Lawrence, T. [US/CA]; 4 Sproule Drive, Brampton, Ontario L6V 4A5 (CA). DAVEY, Cheryl [CA/CA]; 35 Old Orchard Grove, Toronto, Ontario M5M 2C8 (CA). HENDERSON, Graham [CA/CA]; 1110 Walden Circle, Unit #906, Mississauga, Ontario L5G 4R3 (CA). SOOK-NANAN, Roy [CA/CA]; 343 Cedarvale Avenue, Toronto, Ontario M4C 4K5 (CA). (74) Agents: BENT, Stephen, A. et al.; Foley & Lardner, Schwartz, Jeffery, Schwaab, Mack, Blumenthal & Evans, 1800 Diagonal Road, Suite 510, Alexandria, VA 22313 (US). (81) Designated States: AT (European patent), AU, BE (European patent), CA, CH (European patent), DE (European patent)*, DK (European patent), ES (European patent), FI, FR (European patent), GB (European patent), IT (European patent), JP, KR, LU (European patent), NL (European patent), SE (European patent), US. Published <i>With international search report.</i> <i>With amended claims.</i>

(54) Title: ENHANCED NUCLEIC ACID AMPLIFICATION PROCESS**(57) Abstract**

This invention relates to an improved process for amplifying a specific nucleic acid sequence. The process involves synthesizing single-stranded RNA, single-stranded DNA and double-stranded DNA. The single-stranded RNA is a first template for a first primer, the single-stranded DNA is a second template for a second primer, and the double stranded DNA is a third template for synthesis of a plurality of copies of the first template. A sequence of the first primer or the second primer is complementary to a sequence of the specific nucleic acid and a sequence of the first primer or the second primer is homologous to a sequence of the specific nucleic acid. The amplification process may be used to increase the quantity of a specific nucleic acid sequence to allow detection, or to increase the purity of a specific nucleic acid sequence as a substitute for conventional cloning methodology.



DESIGNATIONS OF "DE"

Until further notice, any designation of "DE" in any international application whose international filing date is prior to October 3, 1990, shall have effect in the territory of the Federal Republic of Germany with the exception of the territory of the former German Democratic Republic.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	ES	Spain	MC	Monaco
AU	Australia	FI	Finland	MG	Madagascar
BB	Barbados	FR	France	ML	Mali
BE	Belgium	GA	Gabon	MR	Mauritania
BF	Burkina Faso	GB	United Kingdom	MW	Malawi
BG	Bulgaria	GR	Greece	NL	Netherlands
BJ	Benin	HU	Hungary	NO	Norway
BR	Brazil	IT	Italy	PL	Poland
CA	Canada	JP	Japan	RO	Romania
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	LI	Liechtenstein	SN	Senegal
CM	Cameroon	LK	Sri Lanka	SU	Soviet Union
DE	Germany	LU	Luxembourg	TD	Chad
DK	Denmark			TG	Togo
				US	United States of America

ENHANCED NUCLEIC ACID AMPLIFICATION PROCESS

Field of the Invention

This invention relates to an enhanced process for amplifying a specific nucleic acid sequence.

5

Background of the Invention

The detection of a specific nucleic acid sequence present in a sample by probing the sample with a complementary sequence of nucleic acids is a known diagnostic technique. Nucleic acids are highly specific in binding to complementary nucleic acids and are thus useful to determine whether a specific nucleic acid is present in a sample. One must know the sequence of the specific nucleic acid to be detected and then construct a probe having a complementary nucleic acid sequence to the specific nucleic acid sequence.

10

In this application, the phrase "specific nucleic acid sequence" means a single stranded or double stranded nucleic acid which one wishes to amplify; "sample" means a mixture containing nucleic acids; "sufficiently complementary" means that two

15

20

nucleic acids, a primer and a template, are capable of specific interaction which allows efficient, primer-dependent and template-directed synthesis of DNA, under given conditions of ionic strength and temperature. "DMSO" means dimethyl sulfoxide of sufficient purity to be used in molecular genetic reactions without any ill-effects on substrates or enzymes used; other functionally equivalent alkyl sulfoxides may also be used instead of DMSO. "BSA" means bovine serum albumin of a quality suitable for use in molecular biologic reactions and, in this regard, should be free from any DNases, DNA nicking activity, RNases and proteases. Other functionally equivalent and equally suitable "carrier" proteins may be used in place of BSA.

Since nucleic acid probes are highly specific, it is preferable in some situations to probe the nucleic acid sequence itself rather than the protein produced by the nucleic acid sequence. As a particular example, a diagnostic method based solely on protein detection would be unreliable for determining the presence of infectious Particles of hepatitis B virus, due to the presence of significant levels of non-infectious antigen particles which lack the DNA genome. In another example, the various subtypes of human papilloma virus found in either pre-cancerous or benign cervical tumors can be distinguished only by the use of nucleic acid probe hybridization. Also, the specific genetic makeup of an AIDS virus makes it certain that an assay based on the presence of an AIDS virus specific nucleic acid sequence would be superior as a diagnostic.

The greatest difficulty and limitation with applying existing nucleic acid probe technology, is the copy number problem. In a virus or cell, for example, there is usually a single copy of a particular gene. This one copy may give rise to many copies of gene product, either RNA or protein. For this reason, diagnostic techniques have often involved probing the protein, since the specific sequence of nucleic acid to be detected may give rise to many thousand copies of protein.

The naturally-occurring high number of ribosomal RNA, up to 100,000 copies per cell, has been used by GenProbe to facilitate diagnosis of certain bacterial pathogens, such as Legionella and Mycoplasma, using nucleic acid probes. However, this strategy cannot be used with non-cellular pathogens, such as viruses, or with probed nucleic acid sequences with low copy numbers. Copy number is a particular problem with the development of a nucleic acid probe method for the detection of AIDS virus, where the integrated provirus may be present in less than one of ten thousand peripheral blood lymphocytes. Thus, if the particular nucleic acid sequence suspected to be present in a sample could be amplified, the copy number problem could be circumvented and probe assays could be more readily used.

In a normal biological sample, containing only a few cells, and consequently only a few copies of a particular gene, it is necessary to utilize an amplification process in order to overcome the copy number problem.

One method to amplify is to 'grow out' the sample, that is, to arrange conditions so that the living biological material present in the sample can replicate itself. Replication could increase the quantity of nucleic acid sequences to detectable levels. In the food industry, for example, in order to test processed food for the food-poisoning bacteria Salmonella, food samples must be incubated for a number of days to increase the quantity of nucleic acid copy numbers. In clinical samples, pathogens must also be allowed to increase their number by growing out over some considerable time.

United States Patent No. 4,683,195 issued on July 28, 1987 to Cetus Corporation and United States Patent No. 4,683,202 issued on July 28, 1987 to Cetus Corporation are each directed to a process for amplifying a target nucleic acid sequence contained in a sample. United States Patent No. 4,683,195 relates to a process in which a sample suspected of containing a target DNA sequence is treated with oligonucleotide primers such that a primer extension product is synthesized which in turn serves as a template, resulting in amplification of the target a DNA sequence. The primer extension product is separated from the template in the preferred embodiment using heat denaturation. Similarly, United States Patent No. 4,683,202 relates to a process for amplifying a target DNA sequence having two separate complementary strands. The process includes treating the strands with primers to synthesize extension products, separating the primer extension products from the templates, and in turn using the primer extension products as templates.

Both of the above United States patents require either manual or mechanical participation and multi-step operations by the user in the amplification process and are restricted to amplifying DNA only. The steps involved in these patents require the user to heat the sample, cool the sample, add appropriate enzymes and then repeat the steps. The temperature changes cause the enzymes to loose their activity. Hence, the user is required to repeatedly supplement the amplification mixture with aliquots of appropriate enzymes during the amplification process.

In addition, in United States Patents Nos. 4,683,195 and 4,683,202 each cycle of the amplification process takes place by the synthesis from a first template, of a second template, the second template in turn is used to synthesize the first template. This procedure is repeated, thus, each cycle of the amplification process is based on the synthesis of one product from one substrate.

Notwithstanding the amplification processes disclosed in the prior art, a need exists for improvements to the amplification process. It would be preferable if the amplification process required less participation and fewer manipulations by the user and not be restricted to DNA. Further, it would be advantageous if the amplification took place at a relatively constant ambient temperature so that the activity of the enzymes involved in the process would not be affected. It would be more expedient if a template could be used to generate more than one product from one substrate in each cycle of the amplification process.

Summary of the Invention

This invention relates to an amplification process of single stranded RNA (ssRNA), single-stranded DNA (ssDNA) or double-stranded DNA (dsDNA) which is expedient and requires less participation and fewer manipulations by the user of the process than conventional amplification processes. The amplification takes place at a relatively constant ambient temperature. In addition, each cycle of the process generates a plurality of copies of product from one antisense RNA template. The amplification process of this invention may be used to increase the quantity of a specific nucleic acid thus circumventing the copy number problem. Hence, probe assays may be more readily used. The amplification process could also be used to increase the purity of a specific nucleic acid sequence as a substitute for conventional cloning methodology.

According to one aspect of the invention, a process for amplifying a specific nucleic acid sequence is used. The process involves the synthesis of single-stranded RNA, single-stranded DNA, and double stranded DNA. The single stranded antisense RNA is a first template for a second primer. The single stranded DNA is a second template for a first primer. The double stranded DNA is a third template for the synthesis of a plurality of copies of the first template. A sequence of the first or the second primer is sufficiently complementary to a sequence of the specific nucleic acid sequence and a sequence of the first or the second primer is sufficiently homologous to a sequence of the specific

nucleic acid sequence. A second primer binds to the 3' end of the first RNA template and generates the second DNA template. A 3' end of the first primer hybridizes to the 3' end of the second DNA template.

5 The second template is removed from the first template and is used to generate a complementary DNA strand. The resulting duplex DNA serves as a third template for synthesizing a plurality of first templates which in turn repeat the above-described
10 cycle.

According to another aspect of the invention, a process for amplifying a specific nucleic acid sequence is used. The process involves:

(a) hybridizing a first primer to a first
15 template. The first primer has a DNA sequence which is sufficiently complementary to a RNA sequence of the first template;

(b) synthesizing a first DNA sequence covalently attached to the first primer and
20 complementary to the RNA sequence of the first template. The first DNA sequence and the first primer comprise a second template;

(c) separating the first template from the second template to allow hybridization of a second
25 primer;

(d) hybridizing the second primer to the second template. The second primer has a DNA sequence which is sufficiently complementary to a DNA sequence of the second template. The second primer
30 also has a complementary sequence of a promoter and a complementary sequence of a transcription initiation site for a RNA polymerase;

(e) synthesizing a second DNA sequence covalently attached to the second primer and complementary to the DNA sequence of the second template and synthesizing a third DNA sequence covalently attached to the second template and complementary to the DNA sequence of the second primer. The second and third DNA sequences, the second primer and the second template comprise a third template;

10 (f) synthesizing a plurality of copies of the RNA sequence of the first template from the third template.

Alternatively the amplification process according to the present invention involves the following steps. Step (A) provides a single reaction medium containing a first oligodeoxynucleotide primer, the first primer comprising a sequence that is a functional promoter; a second oligodeoxynucleotide primer, the second primer comprising a 5' end segment complementary to a functional promoter; an RNA-directed DNA polymerase; a DNA-directed DNA polymerase; a DNA-directed RNA polymerase; a ribonuclease that removes RNA of an RNA/DNA hybrid without hydrolyzing single- or double-stranded RNA or DNA; ribonucleoside and deoxyribonucleoside triphosphates; and at least one of DMSO or BSA. Step (B) provides for adding to the reaction medium one or more of the following (i) a single-stranded RNA molecule comprising (a) a sense RNA sequence that hybridizes at its 3' end to a portion of the 3' end of the second primer; or (b) an anti-sense RNA sequence that is hybridized at its 3' end by the first primer, (ii) a single-stranded DNA

molecule comprising (a) a second-primer binding DNA sequence that hybridizes at its 3' end to the 3' end of the second primer; or (b) a promotor-complementary DNA sequence that comprises a 5'-end sequence complementary to a functional promoter; or (c) a first-primer binding DNA sequence that is hybridized at its 5' end by the first primer, (iii) a denatured double-stranded DNA molecule comprising an amplifiable segment and a functional promoter, the functional promoter being adjacent to the segment and oriented to control transcription of the segment. Step (C) provides for establishing conditions such that at least one of the group consisting of a portion of the RNA molecule, the single-stranded DNA molecule and the double-stranded DNA molecule is used as a template for generating one or more copies of the anti-sense RNA sequence and wherein the anti-sense RNA sequence initiates a cycle in the reaction medium comprising the steps of: (i) hybridizing the first primer to a region at the 3' end of the anti-sense RNA sequence; (ii) forming an RNA/DNA hybrid by action of the RNA-directed DNA polymerase, the RNA/DNA hybrid comprising a first DNA segment covalently attached to the 3' end of the first primer to form a second DNA segment, the first DNA segment being complementary to at least a portion of the anti-sense RNA sequence; (iii) releasing the second DNA segment from the RNA/DNA hybrid by action of the ribonuclease on at least some portion of the anti-sense RNA sequence; (iv) hybridizing the 3' end of the second DNA segment with the 3' end of the second primer to form a duplex that is acted upon by the DNA-directed DNA polymerase to produce (a) a third

DNA segment which is covalently attached to the 3' end of the second primer and which is complementary to the first DNA segment, and (b) a fourth DNA segment comprising the third DNA segment and the first primer, and (c) a fifth DNA segment which is covalently attached to the 3' end of the second DNA segment and which is complementary to the non-duplexed 5' end of the second primer, and (d) a sixth DNA segment comprising the second DNA segment and the fifth DNA segment; and (v) producing (a) a plurality of RNA sequences corresponding to the anti-sense RNA sequence by action of the RNA polymerase on the duplex and (b) a plurality of DNA sequences corresponding to the fourth DNA segment and to the sixth DNA segment.

A sequence of the first or the second primer is sufficiently complementary to a sequence of the specific nucleic acid sequence and a sequence of the first or the second primer is sufficiently homologous to a sequence of the specific nucleic acid sequence. A 3' end of the first primer is oriented towards a 3' end of the second primer on complementary strands.

In a further alternative of the invention, the second primer of DNA has a sequence at its 3' end which is sufficiently complementary to the DNA sequence of the second template. The second primer has at its 5' end a complementary sequence of a promoter and a complementary sequence of a transcription initiation site for a RNA polymerase.

In a further alternative of the invention, the third DNA sequence covalently attached to the second template is complementary to the DNA sequence at the 5' end of the second primer.

In another alternative of the invention, a process for amplifying a specific nucleic acid sequence is used. The process involves combining a first primer, a second primer, ribonuclease H, a RNA-directed DNA polymerase, a DNA-directed DNA polymerase, a RNA polymerase, ribonucleoside triphosphates and deoxyribonucleotide triphosphates with a sample. The first primer of DNA has a sequence which is sufficiently complementary to a first template of RNA. The second primer of DNA has a sequence which is sufficiently complementary to a second template of DNA, and a complementary sequence of a promoter and a complementary sequence of a transcription initiation site which are recognized as substrate by the RNA polymerase. A sequence of the first primer or the second primer is sufficiently complementary to a sequence of the specific nucleic acid sequence and a sequence of the first primer or the second primer is sufficiently homologous to a sequence of the specific nucleic acid. A 3' end of the first primer is oriented towards a 3' end of the second primer on complementary strands.

In a further alternative of the invention, a process for amplifying a specific nucleic acid sequence is used. The process involves adding a first primer, a second primer, avian myoblastosis viral polymerase, E. coli ribonuclease H, bacteriophage T7 RNA polymerase, ribonucleoside triphosphates and deoxyribonucleotide triphosphates to a sample. The first primer of DNA has a sequence which is sufficiently complementary to a first template of RNA. The second primer of DNA has a sequence which is sufficiently complementary to a

second template of DNA, and a complementary sequence of a promoter and a complementary sequence of a transcription initiation site which are recognized as substrate by T7 RNA polymerase. A sequence of the first primer or the second primer is sufficiently complementary to a sequence of the specific nucleic acid sequence and a sequence of the first primer or the second primer is sufficiently homologous to a sequence of the specific nucleic acid sequence. A 3' end of the first primer is oriented towards a 3' end of the second primer on complementary strands.

Another aspect of the present invention provides for a kit for amplifying nucleic acid molecules, comprising an assemblage of (a) a receptacle containing a solution of a first oligonucleotide primer, (b) a receptacle containing a solution of a second oligonucleotide primer, (c) a receptacle containing a solution of a ribonuclease that hydrolyses RNA of an RNA/DNA hybrid without attacking single- or double-stranded RNA or DNA, (d) a receptacle containing a solution of an RNA-directed DNA polymerase, (e) a receptacle containing a solution of a DNA-directed RNA polymerase, (f) a receptacle containing a solution of a DNA directed DNA polymerase, (g) a receptacle containing a solution of ribonucleoside triphosphates, (h) a receptacle containing a solution of deoxyribonucleotide triphosphates, (i) a receptacle containing a solution of DMSO, and (j) a receptacle containing a solution of BSA.

According to another aspect of the present invention, a nucleic acid amplification process is provided wherein the DMSO is provided at a

concentration in the in the range from 0-30% and the BSA is provided at a concentration in the range of 5-2500 lg/ml. Alternatively, the DMSO is provided at a concentration in the in the range from 0%-30% and the BSA is provided at a concentration in the range of 50-500 lg/ml. Additionally, the DMSO is provided at a concentration in the in the range from 15-25% and the BSA is provided at a concentration in the range of 50-500 lg/ml.

According to another aspect of the present invention, the amplification with DMSO and BSA is increased over the amplification without added DMSO or BSA at least 10 fold. In another aspect, the amplification is increased over the amplification without added DMSO or BSA at least 1000 fold. In still another aspect of the present invention, the amplification is increased over the amplification without added DMSO or BSA at least 10^4 fold. In another aspect of the present invention, the amplification is increased over the amplification without added DMSO or BSA at least 10^6 fold. In still another aspect of the present invention, the amplification is increased over the amplification without added DMSO or BSA at least 10^8 fold.

25

Brief Description of the Drawings

In drawings which illustrate embodiments of the invention,

5 Figure 1a is a general illustration of the nucleic acid amplification process;

Figure 1b is an example of the nucleic acid amplification process starting with a sense (+) RNA molecule.

10 Figure 1c is an example of the nucleic acid amplification process starting with a dsDNA that has been cut with a restriction endonuclease and then denatured.

15 Figure 1d is an example of the nucleic acid amplification process starting with a dsDNA that has been denatured.

Figure 2 shows the synthetic oligonucleotides DNA sequences which are used for testing the amplification process: Figure 2A, the gag test sequence; Figure 2B, the gag2 test sequence;

20 Figure 3 is an autoradiogram of PAGE analysis of amplification reactions using different primer concentrations;

25 Figure 4 is an autoradiogram of PAGE analysis of amplification reactions using different template concentrations;

Figure 5 is an autoradiogram of Dot-blot hybridization on amplification reactions;

30 Figure 6 is an autoradiogram of PAGE analysis of amplification reaction using restriction fragments as template.

Figure 7 is an ethidium bromide stained agarose gel for a titration of amplification reactions with no HIV target sequence (no template)

using 0-20% DMSO showing effect on non-specific products (NSPs).

5 Figure 8 is an ethidium bromide stained agarose gel of amplification reactions with no template (nt) and 10^4 copies of template using 0% (-) and 15% (+) DMSO showing elimination of NSPs.

10 Figure 9 is an autoradiogram of a slot-blot hybridization analysis of amplification reactions using 0% (-) and 15% (+) DMSO with no template (nt) and 10^3 and 10^4 template copies, showing increased reproducibility and sensitivity.

15 Figure 10A is an ethidium bromide stained agarose gel of amplification reactions with no template (nt) and 10^4 copies of template using 50lg/ml BSA, 0% DMSO and 0% BSA, 15% DMSO and 50 lg/ml BSA, 15% DMSO and 100 lg/ml BSA, and 15% DMSO showing increased sensitivity of the combination of BSA and DMSO for detection of amplified template.

20 Figure 10B is an autoradiogram of a slot-blot hybridization analysis of amplification reactions with no template (nt) and 10^4 copies of template using 50lg/ml BSA, 0% DMSO and 0% BSA, 15% DMSO and 50 lg/ml BSA, 15% DMSO and 100 lg/ml BSA, and 15% DMSO showing increased sensitivity of the combination of BSA and DMSO for detection of amplified template, and for increased reproducibility using DMSO alone.

25 Figure 11 is an autoradiogram of a slot-blot hybridization analysis of amplification reactions with no template (nt) and 10^3 and 10^4 copies of template using 15% DMSO alone and 15% DMSO and 100 lg/ml BSA showing increased sensitivity of the combination of BSA and DMSO for detection of

30

amplified template, and for increased reproducibility using DMSO alone.

Detailed Description of the Preferred Embodiments

5 This invention relates to a process for amplifying a specific nucleic acid sequence. The amplification involves the alternate synthesis of DNA and RNA and is generally and specifically illustrated in Figures 1a-1d. In this process, single-stranded
10 antisense (-) RNA is converted to single-stranded DNA which in turn is converted to dsDNA and becomes a functional template for the synthesis of a plurality of copies of the original single-stranded RNA. A first primer and a second primer are used in the
15 amplification process. A sequence of the first primer or the second primer is sufficiently complementary to a sequence of the specific nucleic acid sequence and a sequence of the first or the second primer is sufficiently homologous to a sequence of
20 the specific nucleic acid sequence. In some instances, both the first primer and second primer are sufficiently complementary and sufficiently homologous to a sequence of the specific nucleic acid sequence, for example, if the specific nucleic acid
25 sequence is double stranded DNA.

 The (-) RNA is converted to single-stranded DNA by hybridizing an oligonucleotide primer (the first primer) to 3' end of the RNA (the first
30 template) and synthesizing a complementary strand of DNA from the first primer (the first DNA sequence) by using a RNA-directed DNA polymerase. The resulting single-stranded DNA (the second template) is separated from the first template by, for example,

hydrolysis of the first template by using a ribonuclease which is specific for RNA-DNA hybrids (for example, ribonuclease H). The second template is converted to a form which is capable of RNA synthesis by hybridizing a synthetic oligonucleotide (the second primer), which contains at its 3' end a sequence which is sufficiently complementary to the 3' end of the second template and toward its 5' end a sequence containing a complementary strand of a promoter and antisense sequence of a transcription initiation site, and by synthesizing a second DNA sequence covalently attached to the 3' end of the second primer using the second template as a template and synthesizing a third DNA sequence covalently attached to the 3' end of the second template using the second primer as a template, using DNA-directed DNA polymerase. The resulting functional derivative of the second template, which is a third template, is used for the synthesis of a plurality of copies of RNA, the first template, by using a RNA polymerase which is specific for the promoter and transcription initiation site defined by the second primer. Each newly synthesized first template can be converted to further copies of the second template and the third template by repeating the cycle. In addition, repetition of the cycle does not require participation or manipulation by the user.

The amplification process commences with the addition of a suitable template nucleic acid to the appropriate enzymes, primers, and cofactors under the appropriate reaction conditions. This template nucleic acid is in a form which is capable of homogenous and continuous amplification and can function

as an intermediate in the cycle set forth in Figure 1a. The amplification process involves the net consumption of precursors (primers, ribonucleoside triphosphates and deoxyribonucleotide triphosphates) and the net accumulation of products (RNA and DNA). The processes of RNA and DNA synthesis will proceed asynchronously until sufficient levels of nucleic acids have been synthesized to allow detection. The amplification process may be monitored by, for example, the synthesis of a labeled product from a labeled precursor.

It is contemplated that amplification may involve another process either in addition to or in place of the one generally illustrated in Figure 1a. Also possible are certain counter-productive enzymatic reactions which occur at permissibly low rates. Included among the possible non-productive side reactions is the synthesis of RNA and/or DNA in the absence of an added template nucleic acid. Such RNA and/or DNA products can be discriminated from desired products by determining whether a particular sequence which would be found only between the two priming sites of the specific nucleic acid sequence is present.

The first primer is an oligodeoxyribonucleotide which has at its 3' end a sequence which is sufficiently complementary to the 3' end of the first template. The sequence at the 3' end of the first primer has a particular length and base composition to allow specific and efficient synthesis of the first DNA sequence, under the given conditions of ionic strength and temperature. The first primer may be sufficiently complementary to a region internal to

the 3' end of the first template in the first cycle. In subsequent cycles, the 5' end of the first primer would be complementary to the 3' end of the first template. It is contemplated that the first primer
5 may be composed partially or completely of nucleotides or nucleotide analogs other than the natural deoxyribonucleotides. The 5' end of the first primer may contain sequences which are not complementary to the first template in the first cycle. The non-
10 complementary sequences may be complementary to a nucleic acid which can be immobilized, or to which can be bound a useful non-nucleic acid component, such as a reporter to facilitate detection. Alternatively, the non-complementary sequences may
15 include a complementary sequence of a promoter and a complementary sequence of a transcription initiation site, which could be used for the synthesis of RNA. This RNA would be complementary to the first template and could be used as an intermediate in another
20 amplification cycle.

The second primer is an oligodeoxyribonucleotide which contains at its 3' end a sequence which is sufficiently complementary to the 3' end of the second template. The second primer has a
25 particular length and base composition to allow specific and efficient synthesis of the second and third DNA sequences, under the given conditions of ionic strength and temperature. In addition, the second primer contains the antisense sequence of a
30 functional promoter and the antisense sequence of a transcription initiation site. This sequence, when used as a template for synthesis of the third DNA sequence, contains sufficient information to allow

specific and efficient binding of a RNA polymerase and initiation of transcription at the desired site. The promoter sequence may be derived from the antisense strand of a functional promoter. The transcription initiation site may be derived from the 5' terminal sequence of a natural RNA transcript. In a preferred embodiment, the 5'-terminal sequence of the second primer is AATTCTAATACGACTCACTATAGGGAG. This sequence contains the antisense sequence of the promoter and the antisense sequence of the transcription initiation site for T7 RNA polymerase. Alternatively, the transcription initiation site and Promoter for another phage RNA polymerase may be used. In addition, sequences which are unrelated to the promoter function may be included at the 5' end of the second primer or between the transcription initiation site and the sequence at the 3' end which hybridizes to the second template. It is contemplated that the second primer may be composed partially or completely of nucleotides or nucleotide analogs other than natural deoxyribonucleotides.

All of the enzymes used in this invention should meet certain practical specifications. Each enzyme or enzyme preparation should be free of deleterious deoxyribonuclease ("DNase") activities, such as the 5' or 3' exonuclease activities which are often associated with certain DNA polymerases and single-strand or double-strand specific exonuclease or endonucleases. Each enzyme or enzyme preparation should be free of deleterious ribonuclease ("RNase") activities, with the exception of the preferred addition of a ribonuclease activity which is specific for hybrids of RNA and DNA (for example, ribonuclease

H). In addition, each enzyme should be reasonably active under the common reaction conditions which are used for the other enzymatic processes, and non-enzymatic processes, such as hybridizing oligonucleotide primers to the RNA or DNA templates.

The DNA-directed RNA polymerase which is used in this invention may be any enzyme capable of binding to a particular DNA sequence called a promoter and specifically initiating in vitro RNA synthesis at a defined initiation site within close proximity to the promoter. The promoter and the initiation site form part of the second primer. In addition the RNA polymerase should be capable of synthesizing several copies of RNA per functional copy of template in a reasonable amount of time. In the preferred embodiment, the bacteriophage T7 RNA polymerase is used. In addition other bacteriophage RNA polymerases, such as phage T3, phage XII, Salmonella phage sp6, or Pseudomonas phage gh-1 may be used. In another embodiment, other prokaryotic or eukaryotic DNA-directed RNA polymerase may be used. It should be understood that if alternative RNA polymerases are used, then the necessary changes to the promoter and initiation sequences of the second primer should be made according to the template specificity of the particular RNA polymerase.

The RNA-directed DNA polymerase which is used in this invention may be any enzyme capable of synthesizing DNA from an oligodeoxyribonucleotide primer and a RNA template. In addition this enzyme may contain activities for DNA-directed DNA polymerase and RNase H. In the preferred embodiment, the avian myoblastosis viral polymerase ("AMV reverse

transcriptase") is used. In addition, the RNA-directed DNA polymerase could be from another retrovirus, such as Maloney murine leukemia virus. Alternatively, other eukaryotic RNA-directed DNA polymerases could be used.

5 The DNA-directed DNA polymerase which is used in this invention may be any enzyme capable of synthesizing DNA from an oligodeoxyribonucleotide primer and a DNA template. This enzyme should not
10 contain either 5'- or 3'- exonuclease activities, which are associated with many types of DNA polymerase. In the preferred embodiment, the AMV reverse transcriptase is used. However, other DNA-directed DNA polymerases which naturally lack the 5'-
15 or 3'- exonuclease activities could be used. These could include certain eukaryotic DNA polymerases, such as, DNA polymerase α or β those DNA polymerases which could be isolated from a mammalian tissue, such as calf thymus. An otherwise unsuitable DNA poly-
20 merase could be made useful by removing the undesirable exonuclease activities either by alteration of the DNA polymerase gene followed by expression of the altered polymerase in a suitable host cell, or by chemical modification of the DNA polymerase protein.
25 Altered versions of DNA polymerase could be made from the Klenow fragment of E. coli DNA polymerase I or the bacteriophage T7 DNA polymerase. It should be understood that such alternative DNA-directed DNA polymerase activities are added to supplement the
30 activity contributed by the RNA-directed DNA polymerase, since in the preferred embodiment, both RNA-directed and DNA-directed DNA polymerase activities are supplied by the same enzyme.

The RNase H which could be used in this invention may be any enzyme capable of hydrolyzing a RNA which is annealed to a complementary DNA. This enzyme should not be capable of hydrolyzing single or
5 double-stranded RNA or any DNA. In the preferred embodiment, the E. coli RNase H is used. In addition, other RNase H enzymes could be used, such as calf thymus RNase H. Since RNase H is an intrinsic activity of AMV reverse transcriptase, the
10 E. coli RNase H will be supplemented in the preferred embodiment by the RNase H of AMV reverse transcriptase. Alternatively, any other enzyme capable of separating the second template from the first template could be used.

15 The above-mentioned enzymes and primers are mixed together in a reaction vessel which contains the necessary buffers and cofactors for both DNA and RNA synthesis. In addition, the ionic conditions and reaction temperature should be compatible with
20 specific hybridization of the primers to the DNA and RNA templates as is known to those skilled in the art. The reaction mixture should be free of such agents which would interfere with the amplification process, specifically substances which could greatly
25 inhibit the activity of the enzymes, interfere with the hybridizing of primers and templates, or degrade non-productively the nucleic acid intermediates and products.

The description of possible detection schemes
30 may be useful to the application of the amplification process. It should be understood that schemes which may be used for detecting the nucleic acids which are synthesized in the amplification process are not

limited to those described herein, and it is contemplated that other methods may be used.

In one embodiment, a labeled precursor may be added to the reaction mixture. Amplification is determined by quantitative or qualitative analysis of labeled products, which can be separated from the labeled precursor by using methods known in the art. A labeled precursor may be a ribonucleoside triphosphate for detecting RNA synthesis, or a deoxynucleoside triphosphate or an oligonucleotide primer for detecting DNA synthesis. The type of label may be a radioisotope or a useful chemical group, such as biotin, a chromophore, a fluorophore, or a hapten which could bind to an antibody, or possibly a protein or an enzyme. The labeled products may be separated from the labeled precursors on the basis of solubility, charge, or size. In addition, the labeled DNA or RNA may be hybridized to a nucleic acid which contains a complementary sequence and which can be immobilized.

In another embodiment, the products of the amplification process may be bound to an immobilized support, hybridized to a nucleic acid probe containing a complementary sequence, and separated from the unhybridized nucleic acid probe which remains in solution. The products, DNA or RNA, may be bound directly to a solid support by any stable interaction, such as hydrophobic, electrostatic, or covalent interaction. In addition, the Products may contain certain chemical groups, for example, biotin, which may be incorporated into the products during the amplification process to allow binding to an immobilized protein, for example, avidin or

streptavidin. In addition, the products may be hybridized to a nucleic acid which contains a complementary sequence and which can be immobilized. The nucleic acid probe would contain a complementary sequence which forms a sufficiently stable interaction with a product of the amplification process to allow binding under the conditions of hybridization and sustained binding under the conditions used for removal of the unhybridized nucleic acid probe. In the preferred embodiment the complementary sequence would be derived from that part of the specific nucleic acid sequence which is between the sequences of the first primer and the second primer. The nucleic acid probe may be a single-stranded DNA or RNA, or a double-stranded DNA or RNA which can be made single-stranded, or an oligonucleotide which can be composed of deoxyribonucleotides and/or ribonucleotides. In addition, the nucleic acid probe may contain a chemical group which could covalently bind to a product DNA or RNA under the appropriate conditions. The nucleic acid probe may be labeled with a radioisotope or a useful chemical group, such as biotin, a chromophore, a fluorophore, or a hapten which could bind to an antibody. In addition, the nucleic acid probe could be conjugated to a protein or enzyme, for example, a phosphatase or a peroxidase. In addition, the nucleic acid probe may contain sequences which would allow in vitro replication of the probe.

It is contemplated that the products of the amplification process may be analyzed by methods which are typically used for nucleic acids that have been enriched by molecular cloning techniques. In

one alternative, the synthesis of a specific DNA sequence may be detected by digestion of the synthesized DNA with a restriction endonuclease, followed by electrophoretic separation and detection using methods known in the art. In another alternative, the sequence of amplified RNA may be determined by DNA synthesis using a RNA-directed DNA Polymerase, the first primer, and dideoxynucleoside triphosphates (Stoflet et al., 1988). In another alternative, the sequence of the amplified third template may be determined by RNA synthesis using the DNA-directed RNA polymerase used in the amplification process, and 3'-deoxyribonucleotide triphosphates (Axelrod & Kramer, 1985). In another alternative, the amplified RNA may encode a polypeptide which could be translated, in vitro. The polypeptide product of the in vitro translation could be analyzed by using an antibody.

A sample suspected of containing or known to contain the specific nucleic acid sequence is added to the reaction mixture in the form of a template nucleic acid which is capable of homogeneous and continuous amplification and may be any intermediate in the cycle set forth in Figure 1. In particular, the template nucleic acid may be a single-stranded RNA which contains at its 5' end a sequence which is sufficiently homologous to that which is at the 3' end of the second primer, and contains a sequence which is sufficiently complementary to the first primer. A template nucleic acid of this form would function as a first template in the amplification process. Alternatively, the template nucleic acid may be a single-stranded DNA which contains at its 3.

end a sequence which is sufficiently complementary to at least the 3' end of the second primer, and contains a sequence which is sufficiently homologous to that which is at the 3' end of the first primer.

5 A template nucleic acid of this form would function as a second template in the amplification process. Alternatively, the template nucleic acid may be a double-stranded DNA, one strand of which contains at its 5' end the entire sequence of the second primer
10 and contains a sequence which is sufficiently complementary to the first primer. The double-stranded DNA functions as a third template in the amplification process.

Although the preparation of a template nucleic acid is not part of the amplification process, the
15 description of possible schemes for generating template nucleic acids may be useful to the application of the amplification process. It should be understood that the schemes which may be used for
20 obtaining the template nucleic acid are not limited to the alternatives which are described herein, and it is contemplated that other methods may be used.

In one alternative, a template nucleic acid which could function as a first template could be a
25 naturally occurring RNA or a RNA fragment which could be generated from a larger RNA molecule by using site specific hydrolysis methods known in the art (Shibahara et al., 1987).

In another alternative, a template nucleic acid which could function as a second template could
30 be generated from a double-stranded DNA by digestion with a restriction endonuclease which has a site immediately flanking the sequence which is

sufficiently complementary to the 3' end of the second primer. The resulting double-stranded DNA fragments could then be made single-stranded by using chemical or thermal denaturation methods.

5 In another alternative, a template nucleic acid which could function as a second template could be generated from a single-stranded DNA or RNA to which has been hybridized an oligonucleotide which is capable of blocking DNA synthesis. This blocking
10 oligonucleotide may contain a chemical group, which could covalently bind to the template, under the appropriate conditions. DNA synthesis from this blocked template using the first primer could result in a synthesized DNA with the same 3' end as the
15 second template. If the original template is RNA, then the resulting DNA-RNA hybrid may be used directly as a template nucleic acid. If the original template is DNA, then the resulting copy of the second template could then be separated from the
20 original template by using chemical or thermal denaturation methods.

 In another alternative, a template nucleic acid which could function as a third template could be generated from a single-stranded DNA or RNA by DNA
25 synthesis from the DNA or RNA template using the second primer. The resulting synthesized DNA could then be separated from the original template by using chemical or thermal denaturation methods. In addition, a RNA template could be hydrolyzed by using
30 chemical or enzymatic methods. The resulting single-stranded DNA has the sequence of the second primer covalently attached to its 5' end and contains a sequence which is sufficiently complementary to the

first primer. This single-stranded DNA could be converted to a transcriptionally functional double-stranded DNA by hybridizing the first primer to the single-stranded DNA, and by synthesizing a DNA
5 sequence which is covalently attached to the first primer and complementary to the single-stranded DNA.

In a further alternative, a single-stranded DNA or RNA template could be obtained from a double-stranded DNA, double-stranded RNA or a DNA-RNA hybrid
10 by using chemical, thermal, or possibly enzymatic methods. Then, by using one of the alternative schemes proposed above, the resulting single-stranded DNA or RNA could then be used to generate a template nucleic acid which could function as a first, second
15 or third template. In addition, an alternative scheme involving the first primer and one strand of nucleic acid, and another alternative scheme involving the second primer and the other (complementary) strand of the nucleic acid may be
20 used concurrently to generate template nucleic acids.

It has been discovered, unexpectedly, that the addition of both DMSO and BSA to the reaction medium significantly increases the sensitivity and reproducibility of the above-described amplification
25 process. Target copy numbers in the range from 1 to 10^6 are detectable and isolateable using the presently claimed invention. DMSO at final concentrations in the range between 0% and 30% and BSA at final concentrations in the range of from 5 μ g/ml to 2500
30 μ g/ml are useful for enhancing the sensitivity and reproducibility of the amplification process. In a preferred embodiment, a BSA concentration of the range from 50 μ g/ml to 500 μ g/ml and a DMSO

concentration in the range from 15% to 25% are used. In another preferred embodiment, a BSA concentration of the range from 100 μ g/ml to 300 μ g/ml and a DMSO concentration in the range from 15% to 25% are used.

5 The use of DMSO and BSA in the amplification reaction medium provides enhanced sensitivity and reproducibility over the use of the reaction medium without DMSO and BSA, however the reaction medium alone is sufficient for the detection and isolation
10 of targeted nucleic acid sequences. The use of DMSO and BSA in the reaction medium is suitable for increasing the amplification level at least 10 fold over that of the reaction medium alone. In a preferred embodiment the amplification using DMSO and
15 BSA according to the presently claimed invention is increased by at least 100 fold. In another preferred embodiment the amplification using DMSO and BSA according to the presently claimed invention is increased by at least 1000 fold. In still another preferred embodiment the amplification using DMSO and
20 BSA according to the presently claimed invention is increased by at least 10,000 fold. In another preferred embodiment the amplification using DMSO and BSA according to the presently claimed invention is increased by at least 10^6 fold. In another preferred
25 embodiment the amplification using DMSO and BSA according to the presently claimed invention is increased by at least 10^7 fold. In another preferred embodiment the amplification using DMSO and BSA according to the presently claimed invention is increased by at least 10^8 fold.
30

Alternatively, the use of other specific enhancement chemicals (SPCs) besides DMSO and BSA could be used according to the present invention that confer increases in amplification level over that of the reaction medium without SPCs.

It has also been discovered, unexpectedly, that the addition of DMSO in the range of 2 to 20 percent to the reaction medium of the presently claimed amplification process has improved the reproducibility of the process, as demonstrated, for example, in Figure 3. The use of DMSO alone, however, is also shown to decrease the amplification level starting between 15% and 20% DMSO in the reaction medium.

MATERIALS AND METHODS

Materials

Oligonucleotides were synthesized using an Applied Biosystems 380A DNA synthesizer. Columns, phosphoramidites, and reagents used for oligonucleotide synthesis were obtained from Applied Biosystems, Inc. through Technical Marketing Associates. Oligonucleotides were purified by polyacrylamide gel electrophoresis followed by DEAE cellulose chromatography. The radioisotope [⁻³²p] UTP (800 Ci/mmol) was from Amersham. Enzymes for digesting and ligating DNA were purchased from New England Biolabs, and used according to the supplier's recommendations. Preparations containing the large fragment of DNA polymerase 1 (Klenow) were also purchased from New England Biolabs. RNasin and T7 RNA polymerase from Promega Biotec were purchased through Bio/Can Scientific Inc. Reverse

transcriptase and RNase H were obtained from Pharmacia. The supplier for proteinase K was Boehringer Mannheim Canada. E. coli strain HB101 (ATCC 33694) was used for all transformations. The
5 plasmid pUC19 (Norrande et al., 1983) was purchased from Bethesda Research Laboratories.

Isolation of DNA and sequencing

E. coli transformants were grown on YT medium (Miller, 1972) containing 50 µg/ml ampicillin.
10 Plasmid DNA was purified by a rapid boiling method (Holmes and Quigley, 1981). DNA fragments and vectors used for all constructions were separated by electrophoresis on low melting point agarose, and purified from the molten agarose by phenol extraction
15 and ethanol precipitation (Maniatis et al., 1982). Plasmid DNA was sequenced using a modification (Hattori et al., 1985) of the dideoxy method (Sanger et al., 1977). Reactions were run using the -20 universal primer (New England Biolabs).

20 TCA precipitation

Aliquots (5ml) of amplification reactions were quenched in 20ml 10 mM EDTA and placed on ice until all time point samples had been collected. The quenched samples were then applied to glass filter
25 discs, and immediately dropped into ice-cold 5% trichloroacetic acid ("TCA") - 1% sodium pyrophosphate for 10 min with occasional mixing. Two 5 min washes with ice-cold 5% TCA were followed by two
30 additional washes with 95% ethanol and lyophilization to dryness. Radioactivity was determined in a liquid scintillation counter.

Polyacrylamide gel electrophoresis

Samples (1 to 6 ml) were mixed with 4-5 ml formamide dye (90% deionized formamide, 10 mM TrisHCl (PH 8.0), 1 mM EDTA, xylene cyanol and bromophenol blue), and applied to a pre-run 12-cm- long 7% denaturing polyacrylamide gel. Gels were run at 350 volts until the bromophenol blue dye had reached the bottom. In some cases the gels were fixed and dried prior to autoradiography. Fixing involved a 15 min wash in 10% methanol- 7% acetic acid. The profiles of the RNA products separated by this procedure were visualized by autoradiography at room temperature.

Example 1: Design and Synthesis of Oligonucleotides For a Gag Test System

A synthetic DNA sequence (Figure 2A) was designed to include an EcoRI site, a T7 phage promoter, a sequence required for initiation of transcription by T7 RNA polymerase and a 19 bp hybridization region (hybridization region 1). The 47 b antisense strand oligonucleotide (T7H1.GAG) involved in the cloning of these elements also serves as the first primer. Hybridization region 2 lies 53 bp away from hybridization region 1 and is 20 bp in length. The primer made to this region (H2.GAG) is a 20 b oligonucleotide duplicate of the sense strand and is not used for cloning. The sequence spanning and including the hybridization regions is a 92 bp segment of the gag portion of the HTLV-III genome, the causative agent of AIDS. This particular gene segment was chosen because the primers were predicted to hybridize efficiently and because the distance

between the two hybridization regions was relatively short. In addition, a XbaI site was placed at the end of the sequence for cloning ease. The gag test sequence test sequence also contains SphI and PstI sites which can aid in the screening of recombinants.

5 A total of four oligonucleotides were used in the cloning of this fragment. N1.GAG, used in the construction of both the gag test and the gag2 test sequence, completes the antisense strand and is used
10 only in the cloning process. Similarly, T74.PRO is the sense strand component of the T7 promoter. N2.GAG however, was used in the construction of both test fragments, and has also been used as an
15 intermediate (second template) in two steps of the amplification cycle. The entire cloned gag test fragment can also represent an intermediate of the amplification cycle (third template). Once cloned into an appropriate vector the gag test DNA could be
20 transcribed by T7 RNA polymerase to produce a RNA fragment (first template) useful as an amplification intermediate involved in three of the steps. In addition, T7H1.GAG and H2.GAG serve as primers in the test system.

The gag2 test synthetic DNA fragment (Figure
25 2B) does not contain the T7 promoter, but the remainder of the sequence is identical to the gag test sequence and therefore, both N1.GAG and N2.GAG were involved in its construction. The oligonucleotide required to complete the antisense strand is
30 called H1.GAG. Once cloned, the gag2 test fragment can be used as a template for testing amplification, using a DNA restriction fragment as template nucleic acid.

Example 2: Construction of the Gag Test Plasmids

The oligonucleotides T74.PRO and N1.GAG (2 mg each), were phosphorylated separately in 20 ml reactions containing 70 mM Tris-HCl (PH 7.6), 10 mM MgCl₂, 5 mM DTT, 0.5 mM ATP and 5 units T4 polynucleotide kinase, at 37°C for 30 min. Phosphorylated T74.PRO and N1.GAG (10 ml of each) were mixed with 1 mg each of unphosphorylated T7H1.GAG and N2.GAG, and 3 ml 100 mM Tris-HCl (PH 7.8) - 500 mM NaCl, in a final volume of 29 ml for the gag test assembly. The gag2 test mixture contained 10 ml phosphorylated N1.GAG, 1 mg each of unphosphorylated H1.GAG and N2.GAG, and 1.8 ml 100 mM Tris-HCl (PH 7.8) - 500 mM NaCl, in a final volume of 18 ml. The oligonucleotide mixtures were hybridized separately by placing them at 90°C for 10 min followed by slow cooling to room temperature for 10 to 16 h 60 ml reactions containing 50 mM Tris-HCl (pH 7.8), 10 mM MgCl₂, 20 mM DTT, 1mM ATP and 50 lg/ml BSA were used to ligate the hybridized oligonucleotides together. 400 units T4 DNA ligase was added to the gag test reaction and it was incubated at 15°C for 2h while the gag2 test reaction was incubated for 14 to 16 h with 200 units T4 DNA ligase.

The isolated and purified synthetic DNA segments were mixed with plasmid pUC19 which had been linearized by digestion at restriction enzyme sites within the polylinker region. T4 DNA ligase was used to ligate the gag test sequence into the EcoRI- XbaI fragment of pUC19, while the gag2 test sequence was ligated to the SmaI-XbaI fragment. Plasmid DNA from transformants obtained after these reactions were used to transform E. coli were screened by

restriction analysis, and the final plasmids (PGAG.TEST and pGAG2.TEST) were determined to be correct by sequence analysis.

Example 3: Effect of Primer Concentration on RNA Amplification

The reaction mixtures (25 ml) which were used to amplify RNA transcribed from the gag test oligonucleotides contained 50 mM Tris-HCl (PH 8.45), 6 mM MgCl₂, 40 mM KCl, 10 mM dithiothreitol, 0.5 mM NTP (ATP, CTP, GTP, UTP), 1 mM dNTP (dATP, dCTP, dGTP dTTP), 20 units RNasin, 10 units T7 RNA polymerase, 10 units reverse transcriptase, 0.4 units RNase H, and 10 mCi [-32p] UTP. Two of the reactions contained 0.5 ng (0.015 pmoles) N2.GAG while the other two reactions contained no template. The primers T7H1.GAG and H2.GAG were each added at final concentrations of 3.4 mM or 0.34 mM to reactions containing either N2.GAG or no template. The reactions were incubated at 42½C for 2 h. Total synthesis of RNA was monitored by determining the incorporation of TCA insoluble cpm at 30 min. intervals. The effect of the primer concentration on template- dependent RNA synthesis is shown in Table 1. Aliquots of each reaction, containing equal amounts of synthesized RNA, were analyzed by PAGE and autoradiography (Figure 3, lanes 1-4 numbered the same as the reactions).

Table 1: RNA amplification from N2.GAG after 2 h.

30 Reaction	Concentration of	Template	RNA Synthesized
	each primer (mM)	(ng)	(mg)
1	3.4	0.5	2.8

37

2	3.4	-	2.1
3	0.34	0.5	1.8
4	0.34	-	0.7

5 It was found that while reaction 1 resulted
in the greatest incorporation of isotope, the no
template control, reaction 2, was also high (73% of
reaction 1) and produced a very similar
electrophoretic profile. It would therefore appear
that in the presence of high primer concentrations,
10 a RNA transcript of identical size to that expected
in amplification is produced in the absence of any
template. Results using samples with a 10-fold
decrease in primer concentration were dramatically
different. The amount of RNA produced in reaction
15 3 was 2.6 times that of reaction 4, but while
virtually all of the transcript was found in a
single band of the expected size in reaction 3, no
fragments greater than 60 to 70 b were found in
reaction 4. Primer concentration therefore plays a
20 significant role in the accuracy and efficiency of
RNA amplification.

A control RNA transcript used to represent
the size of fragment expected to be generated by the
amplification system (lane 0 of Figure 3) was
25 prepared by transcription from the test plasmid.
pGAG.TEST was linearized by digestion with XbaI,
proteinase K treated (Maniatis et al., 1982), phenol
extracted and ethanol precipitated. T7 RNA
polymerase was then used according to the supplier's
30 recommendations to transcribe 0.5 mg of the
resulting fragment in a 25 ml reaction mixture
containing 10 mCi [$-^{32}\text{p}$] UTP.

Example 4: Effect of Template Concentration on RNA Amplification

The standard 50 ml reaction mixture used to amplify RNA transcribed from the gag test oligonucleotides contained 0.34 mM T7H1.GAG, 0.34 mM H2.GAG, 50 mM Tris-HCl (PH 8.45), 6 mM MgCl₂, 40 mM KCl, 10 mM DTT, 0.5 mM NTP, 1 mM dNTP, 40 units RNasin, 20 units T7 RNA polymerase, 20 units reverse transcriptase, 0.8 units RNase H and 10 - 20 mCi [³²p] UTP. The reactions contained amounts of template (N2.GAG) varying from 1 ng to 1 fg. One reaction contained no template. The reactions were incubated at 42½C for 3h, during which total synthesis of RNA was monitored by determining the incorporation of TCA insoluble cpm at 30 min intervals. As indicated in Table 2, total RNA synthesis was higher than the no template control for all template concentrations tested. Although the total synthesis of RNA generally decreased with decreasing template concentration, this decrease in synthesis was not quantitative. Thus, the degree of amplification of RNA per starting template generally increased with decreasing template concentration. Amplification of 8 x 10⁸ fold was achieved by synthesis of 0.8 mg RNA from 1 fg of N2.GAG template. One fg of the 102-b N2.GAG oligonucleotide represents approximately 2 x 10⁴ molecules.

Table 2: RNA amplification from N2.GAG after 3h.

<u>Reaction</u>	<u>Template</u>	RNA	
		<u>Synthesized</u>	<u>Fold</u>
		<u>(mg)</u>	<u>amplification</u>

	1	1 ng	3.5	3.5×10^3
	2	100 pg	4.4	4.4×10^4
	3	10 pg	4.1	4.1×10^5
	4	1 pg	3.0	3.0×10^6
5	5	100 fg	2.7	2.7×10^7
	6	10 fg	1.9	1.9×10^8
	7	1 fg	0.78	7.8×10^8
	8	-	0.046	-

10 The RNA which was synthesized after a
 reaction time of 3h was analyzed by PAGE, for each
 template concentration (Figure 4 lanes 1-8, numbered
 the same as the reactions). A major band
 representing a RNA of about 100 b was present in all
 reactions except the ones containing 1 fg template
 15 and no template. The reaction containing 1 fg
 template did not have much of this 100 b product at
 3 h but the overall RNA
 synthesis was higher than and qualitatively
 different from the no template reaction.

20 Example 5: Hybridization Analysis of RNA Products
 Amplification reactions containing amounts of
 N2.GAG template varying from 1 pg to 0.1 fg were
 performed following the teaching of example 4,
 except the radio labeled UTP was omitted. The
 25 reactions were incubated at $42\frac{1}{2}^{\circ}\text{C}$ for 3 h. Aliquots
 were removed from each reaction at 30 min intervals
 and applied to a nylon membrane (Amersham). The
 nucleic acids that were contained in these reaction
 aliquots were fixed by exposure to ultraviolet
 30 light. The membrane was prehybridized at $50\frac{1}{2}^{\circ}\text{C}$ for
 1 h in prehybridization buffer consisting of a final

concentration of 50% v/v formamide, 5 X SSC and 5 X Denhardt's solution (Maniatis et al, 1982; Southern et al, 1975) at a volume equivalent to 5 mls of solution per 100 cm² and hybridized with a radio
5 labeled probe with a specific activity of 106 cpm/ml of hybridization solution. Hybridization was performed at 50°C for 16 h in 50% formamide, 5 X SSC and 5 X Denhardt's solution (Maniatis et al, 1982; Southern et al, 1975). The radio labeled probe was
10 the synthetic oligonucleotide 5'GATCTGGGATAGAGTACATCCA 3' which had been labeled at the 5' end using T4 polynucleotide kinase and (-32p) ATP. After the membrane was washed at 50°C in a series of 2, 3 min. washes consisting of 2 X SSC,
15 0.1% v/v SDS and 0.2 X SSC, 0.1% v/v SDS (Southern et al, 1975; Maniatis et al, 1982; Szostak et al, 1979).

Figure 5 shows the results of the hybridization analysis performed on the amplification
20 reactions, containing various amounts of N2.GAG template, which were sampled at different times of incubation.

Each column of Figure 5 represents a different time point (1, 30 min; 2, 60 min; 3, 90
25 min; 4, 120 min; 5, 150 min; 6, 180 min) and each row represents a different amount of added N2.GAG template (1, 1pg; 2, 100 fg; 3, 10 fg; 4, 1 fg; 5, 0.1 fg; 6, no template). Amplification of nucleic acids which hybridized to the labeled probe were
30 observed for rows 1-3 (1 pg - 10 fg), however the hybridization to specific nucleic acids in rows 4 - 5 (1 fg, 0.1 fg) was not higher than row 6 (no template). The apparent non-specific binding of

labeled probe in row 6 seems to be related to DNA or RNA synthesis since the hybridization signal increases with increasing time.

5 Example 6: Use of DNA Restriction Fragment as Template.

10 The plasmid pGAG2.TEST was digested with MspI, treated with proteinase K, purified by phenol extraction and ethanol precipitation, and denatured by boiling for 5 min. Amplification reactions were performed and analyzed following the teaching of Example 4, except the MspI digested pGAG2.TEST was used as a template instead of the N2.GAG oligonucleotide. The amounts of plasmid added to each reaction varied from 55 ng to 5.5 pg, and no
15 template. To simulate additional DNA which would be present in an actual sample, alternate reactions contained 1 ng of calf thymus DNA which had been similarly digested, purified and denatured. After a 3 h incubation at 42°C, the synthesis of RNA was
20 determined by TCA precipitation and PAGE analysis. As indicated in Table 3, total RNA synthesis was higher than the no template controls for all template concentrations tested. The degree of amplification was calculated based on RNA synthesis
25 from the actual template which was 1.8% of the total plasmid DNA.

30 The total RNA synthesis (degree of amplification) from a particular initial level template concentration was consistently lower for the restriction fragment (Table 3) as compared to that for the synthetic oligonucleotide template (Table 2). This could be due to competition with

the complementary strand of the restriction fragment template under the conditions used.

Table 3: RNA Amplification From MspI-Digested pGAG2.TEST

5	<u>Reaction</u>	<u>Template*</u>	RNA	Fold
			<u>Synthesized**</u>	<u>amplification**</u>
	1	55.0 ng [1 ng]	3.65	3.7 x 10 ³
	2		(4.05)	(4.1 x 10 ³)
	3	5.5 ng [100 pg]	3.54	3.5 x 10 ⁴
10	4		(3.16)	(3.2 x 10 ⁴)
	5	550.0 pg [10 pg]	2.29	2.3 x 10 ⁵
	6		(2.79)	(2.8 x 10 ⁵)
	7	55.0 pg [1 pg]	2.62	2.6 x 10 ⁶
	8		(0.67)	(0.7 x 10 ⁶)
15	9	5.5 pg [100 fg]	1.37	1.4 x 10 ⁷
	10		(2.26)	(2.3 x 10 ⁷)
	11		1.25	
	12		(0.08)	

* Numbers in brackets indicate equivalent amounts of N2.GAG.

** Numbers in parentheses indicate RNA synthesis in presences of 1 mg MspI-digested calf thymus DNA.

The RNA which was synthesized after a reaction time of 3h was analyzed by PAGE (Figure 6, lanes 1-6, 11 and 12, numbered the same as the reactions). The major band representing a RNA of about 100 b was present in reactions (lanes) 1-6 but absent in the no template reactions (lanes 11 and 12). The RNA in lane 0 was a standard, which was prepared following the teaching of Example 3. There was no apparent qualitative difference in the

synthesized RNA either with (lanes 2, 4 and 6) or without (lanes 1, 3, and 5) the additional of 1 μ g of MspI-digested calf thymus DNA.

Example 7: Use of RNA Fragment as Template

5 The plasmid pGAG.TEST is digested with XbaI, treated with proteinase K, and purified by phenol extraction and ethanol precipitation. RNA of a sequence complementary to N2.GAG is transcribed from the linearized pGAG.TEST plasmid using T7 RNA
10 polymerase. The resulting RNA is purified by digestion with DNase (Promega BioTec, Madison, WI), followed by phenol extraction and ethanol precipitation. The purified RNA is used as a template for amplification reactions following the
15 teaching of Example 5. Amounts of RNA are added to each reaction and vary from 55 ng to 5.5 μ g, and no template. After a 3 h incubation at 42 $\frac{1}{2}$ C, the synthesis of specific RNA is determined by hybridization to labeled oligonucleotide probe,
20 following the teaching of Example 5.

Example 8: Use of Ribosomal RNA as a Template
Amplification of Internal Sequences

Two primers are used for amplifying RNA sequences which are complementary to a part of E. coli 16S ribosomal RNA (rRNA). One of these primers
25 T7HIRIB3.PR2 (AATTCTAATACGACTCACTATAGGGAGTATTACCGCGGCTGCTG) contains the antisense strand of the T7 promoter and initiation site, and a sequence which is complementary to 16S rRNA. The other
30 RIB8.PR (AATACCTTTGCTCATTGACG) is complementary to the DNA synthesized by using T7HIRIB3.PR2 as a

primer and 16S rRNA as a template. A third synthetic oligonucleotide RIB5.PR (AGAAGCACCGGCTAAC) which allows detection of amplification is complementary to the RNA products of the amplification reaction, which are in turn complementary to the original rRNA template.

Reaction mixtures (25 ml) contain 50 mM Tris-HCl (PH 8.45), 6 mM MgCl₂, 40 mM KCl, 10 mM DTT, 0.5 mM NTP, 1 mM dNTP, 20 units RNasin, 10 units T7 RNA polymerase, 10 units AMV reverse transcriptase, 0.4 units RNase H, 0.34 μ m T7H1RIB3.PR2, and 0.34 μ m RIB8.PR.

Amounts of E. coli rRNA varying from 50 ng to 50 fg are added to the reactions. One reaction contains no added rRNA. The reactions are incubated at 42½ for 3 h, during which aliquots are removed at 30, 60, 120, and 180 minutes. The reaction aliquots are quenched, fixed to a nylon membrane, and hybridized to the 32p 5'-end labeled RIB5.PR probe, following the teaching of Example 5.

Example 9: Use of Ribosomal RNA as a Template
Amplification of 5'-Terminal Sequences

Two primers are used for amplifying RNA sequences which are homologous to a part of E. coli 16S rRNA. One of these primers RIB12.PR (TTACTCACCCGTCCGCC) is complementary to 16S rRNA. The other T7H1RIB5.PR (AATTCTAATACGACTCACTATAGGGA-GAAATTGAAGAGTTTGATCAT) is complementary to the 3' end of the DNA synthesized by using RIB12.PR as a primer and 16S rRNA as a template. A third synthetic oligonucleotide RIB11.PR

(GTTCGACTTGTCATGTGTTAGGCCTGCCGCCAGCGTTCAATCTGAGCC)
which allows detection of amplification is
complementary to both the RNA products of the
amplification and the original rRNA template. The
5 amplification reactions for rRNA and detection of
the synthesized RNA are performed following the
teaching of Example 8, except that T7H1RIB5.PR and
RIB12.PR are used as primers (in place of
T7H1RIB3.PR2 and RIB8.PR) and RIB11.PR is used as an
10 oligonucleotide probe (in place of RIB5.PR).

Although preferred embodiments of the
invention have been described in detail, it will be
understood by those skilled in the art that varia-
tions may be made thereto without departing from
15 either the spirit of the invention or the scope of
the appended claims.

Example 10: Specific Enhancement of Nucleic Acid
Amplification Using Dimethylsulfoxide (DMSO) and
Bovine Serum Albumin (BSA).

20 The nucleic acid amplification process, as
exemplified in the above examples, was used with the
following bacterial strains, plasmids and RNA
template were used. A pGEM-3-pol plasmid and an
pUC-pol plasmid each containing a 1450 base pair
25 restriction fragment from HIV 1 (strain HxB2) were
constructed from a BamH1EcoR1 subclone obtained as
a gift from Dr. R. Gallo (NCI, NIH, Bethesda,
Maryland). This restriction fragment contains a
portion of the HIV1 gag gene and the majority of the
30 HIV 1 pol gene. E. coli strain HB101 was
transformed with either the pGEM-3-pol plasmid on
the pUC-pol plasmid. Plasmid DNA was prepared by

methods described in Maniatis et al. MOLECULAR CLONING - A LABORATORY MANUAL p. 86 Cold Spring Harbor Laboratory.

To obtain pol-RNA template, the pGEM-3-pol plasmid was linearized with EcoR1, extracted with phenol-chloroform, and precipitated in ethanol. EcoR1 cuts uniquely at the end of the inserted pol DNA. Purified DNA was transcribed using SP6 RNA polymerase (a suitable RNA polymerase is available from Promega, Madison, WI) according to the method of Melton et al. Nucleic Acids Res 12:7035 (1984). 5 units of RNase-free DNase I (a suitable DNase I is also available from Promega, Madison, WI) was added and the mixture incubated at 37°C for 15 minutes. The RNA product was extracted with phenol-chloroform and precipitated with ethanol. The yield of RNA was determined spectrophotometrically.

The inclusion of DMSO at a final concentration of between 0% and 20% to the reaction mixture used for amplification, as shown in Figure 7, and resulted in a decrease of non-specific products (NSP) from the non-productive side reactions. Figure 8 shows that two types of NSPs designated P1:P1 and P1:P2 were eliminated from the non-target sequence containing samples with the use of 15% DMSO in the reaction medium.

The presence of DMSO in the reaction medium at 15% had the further effect of improving reproducibility of sample run through the claimed amplification process as demonstrated in the slot-blot shown in Figure 9. 10^3 and 10^4 copies of a target sequence were used and the DMSO (indicated by "+") improved the reproducibility as shown by the 5

bands in each lane, but also the sensitivity as shown by comparison of the "+" and "-" lanes under 10^3 copies of target sequence.

When DMSO and BSA (a suitable BSA is available from Boehringer Mannheim, Indianapolis, IN, as special quality for molecular biology) were both used in the reaction medium, the sensitivity and reproducibility were significantly increased, as exemplified in Figures 10A and 10B, which show an increase in amplification of 10^4 copies of a target sequence and both an increase in sensitivity and reproducibility, respectively. Concentrations of 50 μ g/ml and 100 μ g/ml BSA were used with a final concentration of DMSO of 15%. An increase in amplification of at least 100 fold was obtained over the reaction medium without DMSO and BSA, and higher increases were suggested up to 10^8 fold and detection and isolation of as low as a single copy of target were also suggested by the results.

The amplification of both RNA and DNA relative to the presence and absence of DMSO and BSA and to relative to copy number of a target sequence is shown in the slot-blot autoradiogram depicted in Figure 11. Both RNA and DNA were amplified with increase sensitivity and reproducibility using DMSO and BSA in the reaction mixture.

What Is Claimed Is:

1. A process for amplifying a nucleic acid sequence, at a relatively constant temperature and without serial addition of reagents, comprising the steps of:

(A) providing a single reaction medium containing a first oligodeoxynucleotide primer that hybridizes to a 3'-end of an RNA first template and a second oligodeoxynucleotide primer that hybridizes to a 3'-end of a DNA second template, said second primer containing an antisense sequence of a functional promoter; an RNA-directed DNA polymerase; a DNA-directed DNA polymerase; a DNA-directed RNA polymerase; a ribonuclease that hydrolyzes RNA of an RNA-DNA hybrid without hydrolyzing single- or double-stranded RNA or DNA; and ribonucleoside and deoxyribonucleoside triphosphates; and at least one of an alkylated sulfoxide and a suitable carrier protein,

(B) adding to said reaction medium one or more of the following molecules:

- (i) a single-stranded RNA molecule;
- (ii) a single-stranded DNA molecule comprising
 - (a) a primary DNA sequence that hybridizes at its 3'-end to said first primer, wherein the 5'-end of said primary DNA contains the sequence of said second primer; or
 - (b) a second template that hybridizes at its 3'-end to the 3'-end of said second primer, wherein said second contains the sequence of said first primer;
- (iii) a double-stranded DNA comprising a duplex of
 - (a) the sequence of said second template and, covalently attached to the 3'-end thereof, a sense sequence of a functional promoter; and
 - (b) a DNA sequence which contains at its 5'-end the sequence of said second primer;

- (iv) an RNA-DNA hybrid molecule comprising a duplex of
 - (a) said RNA sequence and said primary DNA sequence; or
 - (b) said first template and said second template,

(C) generating a first template from any of the molecules specified in paragraph (B) above using one or more of the ingredients contained in said medium, the 5'-end of said first template containing the 3'-end sequence of said second primer, whereby said first template initiates in said medium a cycle comprising the steps of:

- (i) hybridizing said first primer to said first template;
- (ii) forming an RNA-DNA hybrid by action of said RNA-directed DNA polymerase, said RNA-DNA hybrid comprising a first DNA sequence covalently attached to the 3'-end of said first primer to form a second template;
- (iii) hydrolyzing RNA of said RNA-DNA hybrid with said ribonuclease such that said second primer can bind to said second template;
- (iv) hybridizing said second template to said second primer;

- (v) forming a third template by action of said DNA-directed DNA polymerase, said template comprising a double-stranded, functional promoter and
 - (a) said second primer,
 - (b) a second DNA sequence covalently attached to the 3'-end of said second primer, said second DNA sequence being complementary to at least a portion of said second template,
 - (c) said second template, and
 - (d) a third DNA sequence that is covalently attached to the 3'-end of said second template, said third DNA sequence being complementary to the 5'-end of said second primer, then
- (vi) producing a plurality of first templates by action of said RNA polymerase on said third template, and thereafter
- (D) detecting any one from the group consisting of said first template, said second template, said third template and said RNA-DNA hybrid.

2. A process according to Claim 1, wherein step (D) comprises monitoring the concentration of said plurality of first templates.

3. A process as set forth in Claim 1, wherein said alkyl sulfoxide is DMSO and wherein said suitable carrier protein is BSA.

4. A process according to Claim 1, wherein said alkyl sulfoxide is provided at a concentration in the range from 0-30% and said suitable carrier protein is provided at a concentration in the range of 5-2500 lg/ml.

5. A process according to Claim 1, wherein said alkyl sulfoxide is provided at a concentration in the range from 0-30% and said suitable carrier protein is provided at a concentration in the range of 50-500 lg/ml.

6. A process according to Claim 1, wherein said alkyl sulfoxide is provided at a concentration in the range from 15-25% and said suitable carrier protein is provided at a concentration in the range of 50-500 lg/ml.

7. A process according to Claim 1, wherein the amount of said alkyl sulfoxide and said suitable carrier protein is sufficient to increase said amplification over said amplification without added alkyl sulfoxide or suitable carrier protein at least 10 fold.

8. A process according to Claim 1, wherein the amount of said alkyl sulfoxide and said suitable carrier protein is sufficient to increase said amplification over said amplification without added alkyl sulfoxide or suitable carrier protein at least 100 fold.

9. A process according to Claim 1, wherein the amount of said alkyl sulfoxide and said suitable carrier protein is sufficient to increase said amplification over said amplification without added alkyl sulfoxide or suitable carrier protein at least 1000 fold.

10. A process according to Claim 1, wherein the amount of said alkyl sulfoxide and said suitable carrier protein is sufficient to increase said amplification over said amplification without added alkyl sulfoxide or suitable carrier protein at least 10^4 fold.

11. A process according to Claim 1, wherein the amount of said alkyl sulfoxide and said suitable carrier protein is sufficient to increase said amplification over said amplification without added alkyl sulfoxide or suitable carrier protein at least 10^5 fold.

12. A process according to Claim 1, wherein the amount of said alkyl sulfoxide and said suitable carrier protein is sufficient to increase said amplification over said amplification without added

alkyl sulfoxide or suitable carrier protein at least 10^6 fold.

13. A process according to Claim 1, wherein the amount of said alkyl sulfoxide and said suitable carrier protein is sufficient to increase said amplification over said amplification without added alkyl sulfoxide or suitable carrier protein at least 10^7 fold.

14. A process according to Claim 1, wherein said amplification is increased over said amplification without added alkyl sulfoxide or suitable carrier protein at least 10^8 fold.

15. A process as set forth in Claim 1, wherein said ribonuclease comprises *Escherichia coli* ribonuclease H and ribonuclease H of avian myoblastosis viral polymerase.

16. A process as set forth in Claim 1, wherein said ribonuclease is calf thymus ribonuclease H.

17. A process as set forth in Claim 1, wherein said first or said second oligonucleotide primer is bound reversibly to an immobilized support.

18. A process as set forth in Claim 1, wherein said DNA-directed RNA polymerase is a bacteriophage RNA polymerase and wherein further

said antisense sequence of a functional promoter binds said bacteriophage RNA polymerase.

19. A process as set forth in Claim 18, wherein said DNA-directed RNA polymerase is T7 RNA polymerase and wherein further said antisense sequence of a functional promoter binds said T7 RNA polymerase.

20. A process as set forth in Claim 19, wherein said antisense sequence of a functional promoter comprises the nucleotide sequence

AATTCTAATACGACTCACTATAGGGAG.

21. A process as set forth in Claim 18, wherein said DNA-directed RNA polymerase is phage T3 polymerase and wherein further said antisense sequence of a functional promoter binds said phage T3 polymerase.

22. A process as set forth in Claim 18, wherein said DNA-directed RNA polymerase is phage ϕ II polymerase and wherein further said antisense sequence of a functional promoter binds said phage ϕ II polymerase.

23. A process as set forth in Claim 18, wherein said DNA-directed RNA polymerase is *Salmonella* phage sp6 polymerase and wherein further said antisense sequence of a functional promoter binds said phage sp6 polymerase.

24. A process as set forth in Claim 18, wherein said DNA-directed RNA polymerase is *Pseudomonas* phage gh-1 polymerase and wherein further said antisense sequence of a functional promoter binds said phage gh-1 polymerase.

25. A process as set forth in Claim 1, wherein said RNA-directed DNA polymerase is a retroviral reverse transcriptase.

26. A process as set forth in Claim 25, wherein said retroviral reverse transcriptase is an avian myoblastosis viral polymerase.

27. A process as set forth in Claim 25, wherein said retroviral reverse transcriptase is a Moloney murine leukemia viral polymerase.

28. A process as set forth in Claim 1, wherein all DNA polymerases in said reaction medium lack exonuclease or endonuclease activity.

29. A process as set forth in Claim 1, wherein said DNA-directed DNA polymerase is an avian myoblastosis viral polymerase.

30. A process as set forth in Claim 1, further comprising detecting the presence of the nucleic acid sequence to be amplified by a comparison between an amount of amplification of a first sample suspected to contain the nucleic acid sequence to be amplified and an amount of amplification of a second sample in which the

nucleic acid sequence to be amplified is not present.

31. A process as set forth in Claim 1, further comprising detecting the presence of the nucleic acid sequence to be amplified with a probe.

32. A process as set forth in Claim 1, further comprising detecting the presence of the nucleic acid sequence to be amplified using restriction endonucleases and electrophoretic separation.

33. A process as set forth in Claim 30, further comprising detecting the presence of the nucleic acid sequence to be amplified using restriction endonucleases and electrophoretic separation.

36. A process as set forth in Claim 30, further comprising detecting the presence of the nucleic acid sequence to be amplified with a probe.

37. The specific nucleic acid sequence amplified by the process set forth in Claim 1.

38. A process according to Claim 1, wherein step (B) comprises adding said single-stranded RNA molecule to said reaction medium.

39. A process according to Claim 1, wherein step (B) comprises adding said single-stranded DNA molecule to said reaction medium.

40. A process according to Claim 1, wherein step (B) comprises adding a double-stranded DNA molecule to said reaction medium.

41. A process according to Claim 1, wherein step (D) comprises monitoring the concentration of said second template.

42. A process according to Claim 1, wherein step (D) comprises monitoring the concentration of said third template.

43. A process according to Claim 1, wherein step (D) comprises monitoring the concentration of said RNA-DNA hybrid.

43. A process according to Claim 1, wherein step (D) comprises maintaining said conditions for a period of time between 30 minutes and 4 hours.

44. A process according to Claim 1, wherein an RNA polymerase recognizes said antisense sequence of a functional promoter such that transcription is initiated.

45. A process according to Claim 1, wherein said DNA-directed DNA polymerase is DNA polymerase α or β .

46. A process according to Claim 1, wherein said DNA-directed DNA polymerase is calf thymus DNA polymerase.

47. A process according to Claim 1, wherein said DNA-directed DNA polymerase is a DNA polymerase lacking exonuclease activity.

48. A process according to Claim 1, further comprising the steps of ligating the amplified nucleic acid sequence into a cloning vector and then cloning said nucleic acid sequence or expressing the product encoded by said nucleic acid sequence in an expression system.

49. A kit for amplifying nucleic acid molecules, comprising an assemblage of

- (a) a receptacle containing a solution of a first oligonucleotide primer,
- (b) a receptacle containing a solution of a second oligonucleotide primer,
- (c) a receptacle containing a solution of a ribonuclease that hydrolyses RNA of an RNA/DNA hybrid without attacking single- or double-stranded RNA or DNA,
- (d) a receptacle containing a solution of an RNA-directed DNA polymerase,
- (e) a receptacle containing a solution of a DNA-directed RNA polymerase,
- (f) a receptacle containing a solution of a DNA-directed DNA polymerase,
- (g) a receptacle containing a solution of ribonucleoside triphosphates,
- (h) a receptacle containing a solution of deoxyribonucleotide triphosphates,
- (i) a receptacle containing a solution of alkyl sulfoxide, and
- (j) a receptacle containing a solution of a suitable carrier protein.

AMENDED CLAIMS

[received by the International Bureau on 11 February 1991 (11.02.91);
original claims 1-49 replaced by amended claims 1-54 (13 pages)]

1. A process for the amplification of a specific nucleic acid sequence, at a relatively constant temperature and without serial addition of reagents, comprising the steps of:

(A) providing a single reaction medium containing reagents comprising

- (i) a first oligonucleotide primer,
- (ii) a second oligonucleotide primer comprising an antisense sequence of a promoter recognized by an RNA polymerase,
- (iii) a DNA-directed RNA polymerase that recognizes said promoter,
- (iv) an RNA-directed DNA polymerase,
- (v) a DNA-directed DNA polymerase,
- (vi) a ribonuclease that hydrolyzes RNA of an RNA-DNA hybrid without hydrolyzing single- or double-stranded RNA or DNA,
- (vii) ribonucleoside and deoxyribonucleoside triphosphates;
and
- (viii) at least one of an alkylated sulfoxide and a suitable carrier protein,

then

(B) providing in said reaction medium RNA comprising an RNA first template which comprises said specific nucleic acid sequence or a sequence complementary to said specific nucleic acid sequence, under conditions such that a cycle ensues wherein

- (i) said first oligonucleotide primer hybridizes to said RNA first template,

- (ii) said RNA-directed DNA polymerase uses said RNA first template to synthesize a DNA second template by extension of said first oligonucleotide primer and thereby forms an RNA-DNA hybrid intermediate,
 - (iii) said ribonuclease hydrolyzes RNA which comprises said RNA-DNA hybrid intermediate,
 - (iv) said second oligonucleotide primer hybridizes to said DNA second template,
 - (v) said DNA-directed DNA polymerase uses said second oligonucleotide primer as template to synthesize a functional promoter recognized by said RNA polymerase by extension of said DNA second template;
- and
- (vi) said DNA-directed RNA polymerase recognizes said functional promoter and transcribes said DNA second template, thereby providing copies of said RNA first template;

and thereafter

(C) maintaining said conditions for a time sufficient to achieve a desired amplification of said specific nucleic acid sequence.

2. A process according to Claim 1, wherein said alkyl sulfoxide is dimethylsulfoxide (DMSO) and wherein said carrier protein is bovine serum albumin (BSA).

3. A process according to Claim 1, wherein said alkyl sulfoxide is provided at a concentration in the range of 0-30% and said carrier protein is provided at a concentration in the range of 5-2500 $\mu\text{g/ml}$.

4. A process according to Claim 1, wherein said alkyl sulfoxide is provided at a concentration in the range of 0-30% and said carrier protein is provided at a concentration in the range of 50-500 $\mu\text{g/ml}$.

5. A process according to Claim 1, wherein said alkyl sulfoxide is provided at a concentration in the range of 2-15% and said carrier protein is provided at a concentration in the range of 50-500 $\mu\text{g/ml}$.

6. A process according to Claim 1, wherein the concentration of said alkyl sulfoxide and said carrier protein is sufficient to increase said amplification over said amplification without added alkyl sulfoxide or carrier protein at least 10 fold.

7. A process according to Claim 1, wherein the concentration of said alkyl sulfoxide and said carrier protein is sufficient to increase said amplification over said amplification without added alkyl sulfoxide or carrier protein at least 100 fold.

8. A process according to Claim 1, wherein the concentration of said alkyl sulfoxide and said carrier protein is sufficient to increase said amplification over said amplification without added alkyl sulfoxide or carrier protein at least 1000 fold.

9. A process according to Claim 1, wherein the concentration of said alkyl sulfoxide and said carrier protein is sufficient to increase said amplification over said amplification without

10. A process according to Claim 1, wherein the concentration of said alkyl sulfoxide and said carrier protein is sufficient to increase said amplification over said amplification without added alkyl sulfoxide or carrier protein at least 10^5 fold.

11. A process according to Claim 1, wherein the concentration of said alkyl sulfoxide and said carrier protein is sufficient to increase said amplification over said amplification without added alkyl sulfoxide or carrier protein at least 10^6 fold.

12. A process according to Claim 1, wherein the concentration of said alkyl sulfoxide and said carrier protein is sufficient to increase said amplification over said amplification without added alkyl sulfoxide or carrier protein at least 10^7 fold.

13. A process according to Claim 1, wherein the concentration of said alkyl sulfoxide and said carrier protein is sufficient to increase said amplification over said amplification without added alkyl sulfoxide or carrier protein at least 10^8 fold.

14. A process according to Claim 1, wherein said RNA first template comprises said specific nucleic acid sequence and wherein step (B) comprises providing single-stranded RNA in said reaction medium such that

- (i) said first oligonucleotide primer hybridizes to said single-stranded RNA,

- (ii) said RNA-directed DNA polymerase uses said single-stranded RNA as a template to synthesize a DNA second template by extension of said first oligonucleotide primer and thereby forms an RNA-DNA hybrid,
- (iii) said ribonuclease hydrolyses RNA which comprises said RNA-DNA hybrid,
- (iv) said second oligonucleotide primer hybridizes to said DNA second template,
- (v) said DNA-directed DNA polymerase uses said second oligonucleotide primer as template to synthesize a functional promoter recognized by said RNA polymerase by extension of said DNA second template;
and
- (vi) said DNA-directed RNA polymerase recognizes said functional promoter and transcribes said DNA second template, thereby providing copies of said RNA first template.

15. A process according to Claim 1, wherein said RNA first template comprises a sequence complementary to said specific nucleic acid sequence and wherein step (B) comprises providing single-stranded RNA in said reaction medium such that

- (i) said second oligonucleotide primer hybridizes to said single-stranded RNA,
- (ii) said RNA-directed DNA polymerase uses said RNA as a template to synthesize a complementary DNA by extension of said second oligonucleotide primer and thereby forms an RNA-DNA hybrid,
- (iii) said ribonuclease hydrolyses RNA which comprises said RNA-DNA hybrid,
- (iv) said first oligonucleotide primer hybridizes to said complementary DNA,

66

(v) said DNA-directed DNA polymerase uses said complementary DNA as template to synthesize said DNA second template and a functional promoter recognized by said RNA polymerase by extension of said first oligonucleotide primer;

and

(vi) said DNA-directed RNA polymerase recognizes said functional promoter and transcribes said DNA second template, thereby providing copies of said RNA first template.

16. A process according to Claim 1, wherein step (B) comprises adding to said reaction medium single-stranded DNA which comprises an antisense sequence of a promoter recognized by said RNA polymerase, such that

(i) said first oligonucleotide primer hybridizes to said single-stranded DNA,

(ii) said DNA-directed DNA polymerase uses said single-stranded DNA as template to synthesize said DNA second template and a functional promoter recognized by said RNA polymerase by extension of said first oligonucleotide primer;

and

(iii) said DNA-directed RNA polymerase recognizes said functional promoter and transcribes said DNA second template, thereby providing copies of said RNA first template.

17. A process according to Claim 16, wherein step (B) comprises adding to said reaction medium an RNA-DNA hybrid comprising said single-stranded DNA, such that said ribonuclease hydrolyzes RNA which comprises said RNA-DNA hybrid.

18. A process according to Claim 1, wherein step (B) comprises adding to said reaction medium single-stranded DNA which comprises said DNA second template, such that

- (i) said second oligonucleotide primer hybridizes to said single-stranded DNA,
- (ii) said DNA-directed DNA polymerase uses said second oligonucleotide primer as template to synthesize a functional promoter recognized by said RNA polymerase by extension of said DNA second template;

and

- (iii) said DNA-directed RNA polymerase recognizes said functional promoter and transcribes said DNA second template, thereby providing copies of said RNA first template.

19. A process according to Claim 18, wherein step (B) comprises adding to said reaction medium an RNA-DNA hybrid comprising said single-stranded DNA, such that said ribonuclease hydrolyzes RNA which comprises said RNA-DNA hybrid.

20. A process according to Claim 14, wherein step (B) comprises adding to said reaction medium a DNA comprising a functional promoter recognized by said RNA polymerase, such that said DNA-directed RNA polymerase transcribes said DNA, thereby synthesizing said single-stranded RNA.

21. A process according to Claim 15, wherein step (B) comprises adding to said reaction medium a DNA comprising a functional promoter recognized by said RNA polymerase, such that said DNA-directed RNA polymerase transcribes said DNA, thereby synthesizing said single-stranded RNA.

22. A process according to Claim 1, wherein said second oligonucleotide primer further comprises an antisense sequence of a transcription initiation site for said DNA-directed RNA polymerase, said antisense sequence of said transcription initiation site being operatively linked to said antisense sequence of said promoter.

23. A process according to Claim 22, wherein said DNA-directed RNA polymerase is bacteriophage T7 RNA polymerase and wherein said antisense sequence of a transcription initiation site and said antisense sequence of said promoter together comprise the nucleotide sequence

AATTCTAATACGACTCACTATAGGGAG.

24. A process according to Claim 1, wherein step (B) further comprises adding a sample to said reaction medium under conditions such that, if said sample thereby provides RNA comprising an RNA first template which comprises said specific nucleic acid sequence or a sequence complementary to said specific nucleic acid sequence, said cycle ensues, and wherein said process further comprises, after step (C), a step (D) of monitoring said reaction medium for consumption of any of said reagents (i), (ii) and (vii) or for accumulation of any product of said cycle.

25. A process according to Claim 24, wherein step (D) comprises detecting a nucleic acid product of said cycle.

26. A process according to Claim 25, wherein step (D) comprises detecting said nucleic acid product using a nucleic acid probe.

27. A process according to Claim 25, wherein step (D) comprises detecting said nucleic acid product using restriction endonucleases and electrophoretic separation.

28. A process according to Claim 25, wherein step (D) comprises monitoring the accumulation of said RNA first template.

29. A process according to Claim 25, wherein step (D) comprises monitoring the accumulation of said DNA second template.

30. A process according to Claim 25, wherein step (D) comprises monitoring DNA containing a functional promoter recognized by said RNA polymerase.

31. A process according to Claim 25, wherein step (D) comprises monitoring the accumulation of said RNA-DNA hybrid intermediate.

32. A process according to Claim 24, wherein step (D) further comprises comparing consumption of any reagent of said reagents (i), (ii) and (vii) or accumulation of any product of said cycle with a value representing consumption of said reagent or accumulation of said product in said reaction medium in the absence of said specific nucleic acid sequence and said sequence complementary thereto.

33. A process according to Claim 1, wherein said ribonuclease comprises *Escherichia coli* ribonuclease H.

34. A process according to Claim 1, wherein said ribonuclease comprises calf thymus ribonuclease H.

35. A process according to Claim 1, wherein said first oligonucleotide primer or said second oligonucleotide primer is bound reversibly to an immobilized support.

36. A process according to Claim 1, wherein said DNA-directed RNA polymerase is a bacteriophage RNA polymerase.

37. A process according to Claim 36, wherein said DNA-directed RNA polymerase is bacteriophage T7 RNA polymerase.

38. A process according to Claim 36, wherein said DNA-directed RNA polymerase is bacteriophage T3 polymerase.

39. A process according to Claim 36, wherein said DNA-directed RNA polymerase is bacteriophage ϕ II polymerase.

40. A process according to Claim 36, wherein said DNA-directed RNA polymerase is *Salmonella* bacteriophage sp6 polymerase.

41. A process according to Claim 36, wherein said DNA-directed RNA polymerase is *Pseudomonas* bacteriophage gh-1 polymerase.

42. A process according to Claim 1, wherein said RNA-directed DNA polymerase is a retrovirus reverse transcriptase.

43. A process according to Claim 42, wherein said retrovirus reverse transcriptase is avian myeloblastosis virus polymerase.

44. A process according to Claim 42, wherein said retrovirus reverse transcriptase is a Moloney murine leukemia virus polymerase.

45. A process according to Claim 1, wherein said DNA-directed DNA polymerase lacks exonuclease activity.

46. A process according to Claim 1, wherein all DNA polymerases in said reaction medium lack DNA exonuclease and endonuclease activity.

47. A process according to Claim 1, wherein said DNA-directed DNA polymerase is avian myeloblastosis virus polymerase.

48. A process according to Claim 1, wherein said DNA-directed DNA polymerase is DNA polymerase α or DNA polymerase β .

49. A process according to Claim 1, wherein said DNA-directed DNA polymerase is calf thymus DNA polymerase.

50. A process according to Claim 1, wherein step (C) comprises maintaining said conditions for a time between 30 minutes and 4 hours.

51. A process according to Claim 1, further comprising the steps of ligating a DNA product of said cycle into a cloning vector and then cloning said DNA product.

52. A process according to Claim 51, further comprising the step of expressing a product encoded by said DNA product of said cycle in an expression system.

53. A kit for amplifying nucleic acid sequences, comprising an assemblage of

- (a) a receptacle containing a first oligonucleotide primer,
- (b) a receptacle containing a second oligonucleotide primer comprising an antisense sequence of a promoter recognized by an RNA polymerase,
- (c) a receptacle containing a DNA-directed RNA polymerase that recognizes said promoter,
- (d) a receptacle containing an RNA-directed DNA polymerase,
- (e) a receptacle containing a DNA-directed DNA polymerase,
- (f) a receptacle containing a ribonuclease that hydrolyzes RNA of an RNA-DNA hybrid without hydrolyzing single- or double-stranded RNA or DNA,
- (g) a receptacle containing ribonucleoside triphosphates,
- (h) a receptacle containing deoxyribonucleoside triphosphates, and
- (i) a receptacle containing at least one of an alkylated sulfoxide and a suitable carrier protein.

54. A process according to Claim 1, wherein said alkyl sulfoxide is provided at a concentration of about 15% and said carrier protein is provided at a concentration in the range of 50-500 $\mu\text{g/ml}$.

1/11




FIG. 1A

SUBSTITUTE SHEET

2/11

FIG. 1B

NATURAL RNA TARGET 5' nnn C B A nnnnnnnnnnnn 3'
 1st OLIGO. PRIMER 3' a' i' p' 5'

1. REVERSE TRANSCRIPTASE + dNTP's

NATURAL RNA TARGET 5' nnn C B A nnnnnnnnnnnn 3'
 1st DNA SEGMENT 3' nnn c' b' a' i' p' 5'

2. RIBONUCLEASE H

1st DNA SEGMENT 3' nnn c' b' a' i' p' 5'

3. PRIMING

2nd OLIGO. PRIMER 5' C 3'
 1st DNA SEGMENT 3' nnn c' b' a' i' p' 5'

4. REVERSE TRANSCRIPTASE + dNTP's

2nd DNA SEGMENT 5' C I P 3'
 1st DNA SEGMENT 3' nnn c' b' a' i' p' 5'

5. T7 RNA POLYMERASE + NTP's

RNA PRODUCT 3' c' b' a' i' 5'

6. PRIMING

2nd OLIGO. PRIMER 5' C 3'
 RNA PRODUCT 3' c' b' a' i' 5'

7. REVERSE TRANSCRIPTASE + dNTP's

2nd DNA SEGMENT 5' C B A I 3'
 RNA PRODUCT 3' c' b' a' i' 5'

8. RIBONUCLEASE H

2nd DNA SEGMENT 5' C B A I P 3'

9. PRIMING

2nd DNA SEGMENT 5' C B A I 3'
 1st OLIGO. PRIMER 3' a' i' p' 5'

10. REVERSE TRANSCRIPTASE + dNTP's

2nd DNA SEGMENT 5' C B A I P 3'
 1st DNA SEGMENT 3' c' b' a' i' p' 5'

11. T7 RNA POLYMERASE + NTP's

RNA PRODUCT 3' c' b' a' i' 5'

SUBSTITUTE SHEET

3/11

FIG. 1C

NATURAL DNA TARGET: 1 5'

nnn	C		B		A	nnnnnnnnnnnnnnnn
-----	---	--	---	--	---	------------------

 3'

NATURAL DNA TARGET: 2 3'

nnn	c'		b'		a'	nnnnnnnnnnnnnnnn
-----	----	--	----	--	----	------------------

 5'

1. RESTRICTION ENZYME

NATURAL DNA TARGET: 1 5'

nnn	C		B		A
-----	---	--	---	--	---

 3'

NATURAL DNA TARGET: 2 3'

nnn	c'		b'		a'
-----	----	--	----	--	----

 5'

2. DENATURE

NATURAL DNA TARGET: 1 5'

nnn	C		B		A
-----	---	--	---	--	---

 3'

NATURAL DNA TARGET: 2 3'

nnn	c'		b'		a'
-----	----	--	----	--	----

 5'

3. PRIMING

NATURAL DNA TARGET: 1 5'

nnn	C		B		A
-----	---	--	---	--	---

 3'

1st OLIGO. PRIMER 3'

	a'	i'	p'
--	----	----	----

 5'

4. REVERSE TRANSCRIPTASE + dNTP's

NATURAL DNA TARGET: 1 5'

nnn	C		B		A	I	P
-----	---	--	---	--	---	---	---

 3'

1st DNA SEGMENT 3'

nnn	c'		b'		a'	i'	p'
-----	----	--	----	--	----	----	----

 5'

5. T7 RNA POLYMERASE + NTP's

RNA PRODUCT 3'

c'		b'		a'	i'
----	--	----	--	----	----

 5'

6. PRIMING

2nd OLIGO. PRIMER 5'

C

 3'

RNA PRODUCT 3'

c'		b'		a'	i'
----	--	----	--	----	----

 5'

7. REVERSE TRANSCRIPTASE + dNTP's

2nd DNA SEGMENT 5'

C		B		A	I
---	--	---	--	---	---

 3'

RNA PRODUCT 3'

c'		b'		a'	i'
----	--	----	--	----	----

 5'

8. RIBONUCLEASE H

2nd DNA SEGMENT 5'

C		B		A	I	P
---	--	---	--	---	---	---

 3'

9. PRIMING

2nd DNA SEGMENT 5'

C		B		A	I
---	--	---	--	---	---

 3'

1st OLIGO. PRIMER 3'

	a'	i'	p'
--	----	----	----

 5'

10. REVERSE TRANSCRIPTASE + dNTP's

2nd DNA SEGMENT 5'

C		B		A	I	P
---	--	---	--	---	---	---

 3'

1st DNA SEGMENT 3'

c'		b'		a'	i'	p'
----	--	----	--	----	----	----

 5'

II. T7 RNA POLYMERASE + NTP's

RNA PRODUCT 3'

c'		b'		a'	i'
----	--	----	--	----	----

 5'

SUBSTITUTE SHEET

FIG. 1D

NATURAL DNA TARGET: 1 5' nnn C B A nnnnnnnnnnn 3'
 NATURAL DNA TARGET: 2 3' nnn c' b' a' nnnnnnnnnnn 5'

I. DENATURE

NATURAL DNA TARGET: 1 5' nnn C B A nnnnnnnnnnn 3'
 NATURAL DNA TARGET: 2 3' nnn c' b' a' nnnnnnnnnnn 5'

2. PRIMING

NATURAL DNA TARGET: 1 5' nnn C B A nnnnnnnnnnn 3'
 1st OLIGO. PRIMER 3' a' i' p' 5'

3. REVERSE TRANSCRIPTASE + dNTP's

NATURAL DNA TARGET: 1 5' nnn C B A nnnnnnnnnnn 3'
 1st DNA SEGMENT 3' nnn c' b' a' i' p' 5'

4. DENATURE

NATURAL DNA TARGET: 1 5' nnn C B A nnnnnnnnnnn 3'
 1st DNA SEGMENT 3' nnn c' b' a' i' p' 5'

5. PRIMING

2nd OLIGO. PRIMER 5' C 3'
 1st DNA SEGMENT 3' nnn c' b' a' i' p' 5'

6. REVERSE TRANSCRIPTASE + dNTP's

2nd DNA SEGMENT 5' C B A I P 3'
 1st DNA SEGMENT 3' nnn c' b' a' i' p' 5'

7. T7 RNA POLYMERASE + NTP's

RNA PRODUCT 3' c' b' a' i' 5'

8. PRIMING

2nd OLIGO. PRIMER 5' C 3'
 RNA PRODUCT 3' c' b' a' i' 5'

9. REVERSE TRANSCRIPTASE + dNTP's

2nd DNA SEGMENT 5' C B A I 3'
 RNA PRODUCT 3' c' b' a' i' 5'

10. RIBONUCLEASE H

2nd DNA SEGMENT 5' C B A I P 3'

11. PRIMING

2nd DNA SEGMENT 5' C B A I 3'
 1st OLIGO. PRIMER 3' a' i' p' 5'

12. REVERSE TRANSCRIPTASE + dNTP's

2nd DNA SEGMENT 5' C B A I P 3'
 1st DNA SEGMENT 3' c' b' a' i' p' 5'

13. T7 RNA POLYMERASE + NTP's

RNA PRODUCT 3' c' b' a' i' 5'

SUBSTITUTE SHEET

FIG. 2A

T7H1.GAG
AATTCTAATACGACTCATTATAGGGAGACAATAGGCCCTGCATGCAC↓TGGATGTACTCTATCCCAT

GATTATGCTGAGTGATAT↓CCCCTCTGTTATCCGGGACGTACGTGACCTACATGAGATAGGGTA
T74.PRO

N1.GAG
TCTGCAGCTTCCTCATTGATGGGTCCTTTTAACATTTCATGGCTGCTTGA↓GT

AGACGTCGAAGGAGTAAC↓TAC CAGAGAAA↓TGTAAACG↓TACC GACGAAC↓TACAGATC
124
N2.GAG
TAAACG TACC GACGAAC TACAGATC
(H2.GAG)

FIG. 2B

H1.GAG
GGGAGACAATAGGCCCTGCATGCAC↓TGGATGTACTCTATCCCAT

CCCTCTGTTATCCGGGACGTACGTGACCTACATGAGATAGGGTA

N1.GAG
TCTGCAGCTTCCTCATTGATGGGTCCTTTTAACATTTCATGGCTGCTTGA↓GT

AGACGTCGAAGGAGTAAC↓TAC CAGAGAAA↓TGTAAACG↓TACC GACGAAC↓TACAGATC
124
N2.GAG
TAAACG TACC GACGAAC TACAGATC
(H2.GAG)

6/11




FIG. 4



FIG. 3

SUBSTITUTE SHEET

7/11

FIG. 5





FIG. 10B




1	6	11	16	21
2	7	12	17	22
3	8	13	18	23
4	9	14	19	24
5	10	15	20	25

SUBSTITUTE SHEET

8/11

FIG. 6



SUBSTITUTE SHEET




FIG. 7




FIG. 8

SUBSTITUTE SHEET

10/11

FIG. 9






FIG. II



SUBSTITUTE SHEET

FIG. 10A



INTERNATIONAL SEARCH REPORT

International Application No PCT/US 90/04733

I. CLASSIFICATION OF SUBJECT MATTER (If several classification symbols apply, indicate all) ⁶ According to International Patent Classification (IPC) or to both National Classification and IPC IPC5: C 12 Q 1/68														
II. FIELDS SEARCHED <div style="text-align: right; margin-right: 100px;">Minimum Documentation Searched⁷</div> <table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 25%; padding: 5px;">Classification System</td> <td style="padding: 5px;">Classification Symbols</td> </tr> <tr> <td style="padding: 5px;">IPC5</td> <td style="padding: 5px;">C 12 Q</td> </tr> </table> <div style="text-align: center; margin-top: 5px;">Documentation Searched other than Minimum Documentation to the Extent that such Documents are Included in Fields Searched⁸</div>			Classification System	Classification Symbols	IPC5	C 12 Q								
Classification System	Classification Symbols													
IPC5	C 12 Q													
III. DOCUMENTS CONSIDERED TO BE RELEVANT⁹ <table border="1" style="width: 100%; border-collapse: collapse;"> <thead> <tr> <th style="width: 10%; padding: 5px;">Category *</th> <th style="width: 60%; padding: 5px;">Citation of Document,¹¹ with indication, where appropriate, of the relevant passages¹²</th> <th style="width: 30%; padding: 5px;">Relevant to Claim No.¹³</th> </tr> </thead> <tbody> <tr> <td style="padding: 5px; vertical-align: top;">P,X</td> <td style="padding: 5px; vertical-align: top;">EP, A2, 0329822 (CANGENE CORPORATION) 30 August 1989, see the whole document --</td> <td style="padding: 5px; vertical-align: top; text-align: center;">1-49</td> </tr> <tr> <td style="padding: 5px; vertical-align: top;">P,X</td> <td style="padding: 5px; vertical-align: top;">Proc.Natl.Acad.Sci., Vol. 87, 1990,(USA) John C. Guatelli et al: "Isothermal, in vitro amplification of nucleic acids by a multienzyme reaction modeled after retroviral replication", see page 1874 - page 1878 --</td> <td style="padding: 5px; vertical-align: top; text-align: center;">1-49</td> </tr> <tr> <td style="padding: 5px; vertical-align: top;">P,X</td> <td style="padding: 5px; vertical-align: top;">EP, A2, 0373960 (SISKA DIAGNOSTICS, INC.) 20 June 1990, see the whole document --</td> <td style="padding: 5px; vertical-align: top; text-align: center;">1-49</td> </tr> </tbody> </table>			Category *	Citation of Document, ¹¹ with indication, where appropriate, of the relevant passages ¹²	Relevant to Claim No. ¹³	P,X	EP, A2, 0329822 (CANGENE CORPORATION) 30 August 1989, see the whole document --	1-49	P,X	Proc.Natl.Acad.Sci., Vol. 87, 1990,(USA) John C. Guatelli et al: "Isothermal, in vitro amplification of nucleic acids by a multienzyme reaction modeled after retroviral replication", see page 1874 - page 1878 --	1-49	P,X	EP, A2, 0373960 (SISKA DIAGNOSTICS, INC.) 20 June 1990, see the whole document --	1-49
Category *	Citation of Document, ¹¹ with indication, where appropriate, of the relevant passages ¹²	Relevant to Claim No. ¹³												
P,X	EP, A2, 0329822 (CANGENE CORPORATION) 30 August 1989, see the whole document --	1-49												
P,X	Proc.Natl.Acad.Sci., Vol. 87, 1990,(USA) John C. Guatelli et al: "Isothermal, in vitro amplification of nucleic acids by a multienzyme reaction modeled after retroviral replication", see page 1874 - page 1878 --	1-49												
P,X	EP, A2, 0373960 (SISKA DIAGNOSTICS, INC.) 20 June 1990, see the whole document --	1-49												
<div style="display: flex; justify-content: space-between;"> <div style="width: 45%;"> <p>[*] Special categories of cited documents: ¹⁰</p> <p>^{"A"} document defining the general state of the art which is not considered to be of particular relevance</p> <p>^{"E"} earlier document but published on or after the international filing date</p> <p>^{"L"} document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>^{"O"} document referring to an oral disclosure, use, exhibition or other means</p> <p>^{"P"} document published prior to the international filing date but later than the priority date claimed</p> </div> <div style="width: 45%;"> <p>^{"T"} later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>^{"X"} document of particular relevance, the claimed invention cannot be considered novel or cannot be considered to involve an inventive step</p> <p>^{"Y"} document of particular relevance, the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.</p> <p>^{"&"} document member of the same patent family</p> </div> </div>														
IV. CERTIFICATION <table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 50%; padding: 5px;"> Date of the Actual Completion of the International Search 20th November 1990 </td> <td style="width: 50%; padding: 5px;"> Date of Mailing of this International Search Report <div style="text-align: center; font-size: 1.2em;">10 DEC. 1990</div> </td> </tr> <tr> <td style="width: 50%; padding: 5px;"> International Searching Authority <div style="text-align: center;">EUROPEAN PATENT OFFICE</div> </td> <td style="width: 50%; padding: 5px;"> Signature of Authorized Officer <div style="text-align: center;">MISS T. TAZELAR</div> </td> </tr> </table>			Date of the Actual Completion of the International Search 20th November 1990	Date of Mailing of this International Search Report <div style="text-align: center; font-size: 1.2em;">10 DEC. 1990</div>	International Searching Authority <div style="text-align: center;">EUROPEAN PATENT OFFICE</div>	Signature of Authorized Officer <div style="text-align: center;">MISS T. TAZELAR</div>								
Date of the Actual Completion of the International Search 20th November 1990	Date of Mailing of this International Search Report <div style="text-align: center; font-size: 1.2em;">10 DEC. 1990</div>													
International Searching Authority <div style="text-align: center;">EUROPEAN PATENT OFFICE</div>	Signature of Authorized Officer <div style="text-align: center;">MISS T. TAZELAR</div>													

III. DOCUMENTS CONSIDERED TO BE RELEVANT (CONTINUED FROM THE SECOND SHEET)		
Category *	Citation of Document, with indication, where appropriate, of the relevant passages	Relevant to Claim No
A	EP, A1, 0310229 (THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY) 5 April 1989, see the whole document --	1-49
A	EP, A2, 0303155 (MERCK PATENT GESELLSCHAFT MIT BESCHRÄNKTER HAFTUNG) 15 February 1989, see the whole document --	1-49
A	Dialog Information Services, File 351, World Patent Index 81-90, Dialog accession no. 88-096821/14, Yamashina I: "Gene, for supplying thrombin-like batr oxobin enzyme - used for coding polypeptide contg. batroxobin amino acid sequence", JP 63049084, A, 880301, 8814 (Basic) --	1-49
A	EP, A2, 0272098 (CITY OF HOPE NATIONAL MEDICAL CENTER) 22 June 1988, see the whole document --	1-49
A	WO, A1, 8810315 (SISKA DIAGNOSTICS, INC.) 29 December 1988, see the whole document --	1-49
A	Nucleic Acids Research, Vol. 17, No. 3, 1989, Peter R. Winship: "An improved method for directly sequencing PCR amplified material using dimethyl sulphoxide ", see page 1266 -- -----	1-49

**ANNEX TO THE INTERNATIONAL SEARCH REPORT
ON INTERNATIONAL PATENT APPLICATION NO. PCT/US 90/04733**

SA 40019

This annex lists the patent family members relating to the patent documents cited in the above-mentioned international search report. The members are as contained in the European Patent Office EDP file on 01/11/90. The European Patent office is in no way liable for these particulars which are merely given for the purpose of information.

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP-A2- 0329822	30/08/89	JP-A- 2005864	10/01/90
EP-A2- 0373960	20/06/90	AU-D- 4829690 WO-A- 90/06995	10/07/90 28/06/90
EP-A1- 0310229	05/04/89	AU-D- 2318188 JP-T- 2501532 WO-A- 89/01050	01/03/89 31/05/90 09/02/89
EP-A2- 0303155	15/02/89	DE-A- 3726934 JP-A- 1071500	23/02/89 16/03/89
EP-A2- 0272098	22/06/88	NONE	
WO-A1- 8810315	29/12/88	AU-D- 2126588 EP-A- 0368906 JP-T- 2500565	19/01/89 23/05/90 01/03/90

For more details about this annex : see Official Journal of the European patent Office, No. 12/82

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ **BLACK BORDERS**
- ☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- ☒ **FADED TEXT OR DRAWING**
- ☒ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- ☐ **SKEWED/SLANTED IMAGES**
- ☐ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- ☐ **GRAY SCALE DOCUMENTS**
- ☒ **LINES OR MARKS ON ORIGINAL DOCUMENT**
- ☐ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- ☐ **OTHER:** _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.